<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     f10k_032621p.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        UNITED STATES SECURITIES AND EXCHANGE COMMISSION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Washington, D. C. 20549       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.75in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         FORM 1O-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        (Mark One)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 18.75pt">           <font style="font-family: Wingdings; font-size: 10pt">           </font>           ☒          </td>          <td>           ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        ACT OF 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For the fiscal year ended December 31, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        OR       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 18.75pt">           <font style="font-family: Wingdings; font-size: 10pt">            ¨           </font>          </td>          <td>           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.75pt">        EXCHANGE ACT OF 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For the transition period from __________to ____________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Commission file number        <u>         1-10526        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          UNITED-GUARDIAN, INC.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Exact name of Registrant as specified inits charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; width: 49%; padding-bottom: 1pt">           <u>            Delaware           </u>          </td>          <td style="width: 2%">          </td>          <td style="text-align: center; width: 49%; padding-bottom: 1pt">           <u>            11-1719724           </u>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; padding-bottom: 1pt">           (State or other jurisdiction          </td>          <td>          </td>          <td style="text-align: center">           (I.R.S. Employer          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; padding-bottom: 1pt">           of incorporation or organization)          </td>          <td>          </td>          <td style="text-align: center">           Identification No.)          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <u>         230 Marcus Blvd., Hauppauge, NY 11788        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Address of principal executive offices,including zip code)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <u>         (631) 273-0900         <font style="color: white">          .         </font>         <br/>        </u>        Registrant's telephone number, including area code       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Securities registered pursuant to Section l2(b) of the Act:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 31%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">           <u>            Title of each class           </u>          </td>          <td style="width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center">           <u>            Trading Symbol(s)           </u>          </td>          <td style="width: 47%; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center">           <u>            Name of each exchange on which registered           </u>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">           Common Stock, $.10 par value          </td>          <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">           UG          </td>          <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">           The NASDAQ Global Market          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section12(g) of the Act:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <u>         None        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Indicate by check mark if theRegistrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐   No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Indicate by checkmark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes ☐    No ☒       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            Cover Page            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->            of 2           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Indicate by check markwhether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 7in">        Yes ☒  No ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Indicate by check mark whether the registranthas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch ﬁles). Yes  ☒ No ☐        <font style="font-family: Wingdings">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Indicate by check markwhether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 28%">           <font style="font-size: 10pt">            Large accelerated filer           </font>          </td>          <td style="width: 5%">           ☐          </td>          <td style="width: 16%">          </td>          <td style="width: 43%">           <font style="font-size: 10pt">            Smaller reporting company           </font>          </td>          <td style="width: 8%">           ☒          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Accelerated filer           </font>          </td>          <td>           ☐          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Emerging growth company           </font>          </td>          <td>           ☐          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Non-accelerated filer           </font>          </td>          <td>           ☒          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 6.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        </font>        ☐       </p>       <p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.        </font>        ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes        </font>        <font style="font-family: Wingdings">        </font>        ☐        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         No        </font>        ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of June 30, 2020,the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of thevoting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was lastsold, or the average bid and asked price of such common equity, was approximately $48,900,000. (For the purpose of this reportit has been assumed that all officers and directors of the Registrant, as well as all stockholders holding 10% or more of Registrant'sstock, are affiliates of the Registrant).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        APPLICABLE ONLY TO REGISTRANTS INVOLVEDIN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) ofthe Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes        </font>        <font style="font-family: Wingdings">        </font>        ☐        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         No☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of March 1, 2021,the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock").       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        DOCUMENTS INCORPORATED BY REFERENCE:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Certain informationrequired by Part III (portions of Item 10, as well as Items 11, 12, and 13) is incorporated by reference to the Registrant's definitiveproxy statement for the 2021 annual meeting of stockholders ("2021 Proxy Statement"), which, pursuant to Regulation 14Aof the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is to be filed with the Securities and ExchangeCommission (the “SEC”) no later than 120 days after Registrant's fiscal year end.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            Cover Page            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->            of 2           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This Annual Reporton Form 10-K (“Annual Report”) contains both historical and forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995, which provides a safe harbor for forward-looking statements by the Registrant about itsexpectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters. The Registrantdesires to take advantage of such "safe harbor" provisions and is including this statement for that express purpose.Words such as "anticipates", "believes", "expects", "intends", "future", andsimilar expressions identify forward-looking statements. Any such forward-looking statements in this report reflect the Registrant'sviews as of the date of filing of this report with the United States Securities and Exchange Commission (the “SEC”)with respect to future events and financial performance, and are subject to a variety of factors that could cause the Registrant'sactual results or performance to differ materially from historical results or from the anticipated results or performance expressedor implied by such forward-looking statements. Because of such factors, there can be no assurance that the actual results or developmentsanticipated by the Registrant will be realized or, even if substantially realized, that they will have the anticipated results.The risks and uncertainties that may affect the Registrant's business include, but are not limited to: economic conditions, governmentalregulations, technological advances, pricing and competition, acceptance by the marketplace of new products, retention of key personnel,the sufficiency of financial resources to sustain and expand the Registrant's operations, and other factors described in this reportand in prior filings with the SEC. Readers should not place undue reliance on such forward-looking statements, which speak onlyas of the date hereof, and should be aware that except as may be otherwise legally required of the Registrant, the Registrant undertakesno obligation to publicly revise any such forward-looking statements to reflect events or circumstances that may arise after thedate hereof.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PART I        </b>       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 1.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            <u>             Business            </u>           </b>           <u>            .           </u>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (a)        <b>         <u>          Introduction         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        United-Guardian, Inc.("United", "Registrant", or “Company”) is a Delaware corporation that, through its Guardian Laboratoriesdivision, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products.It also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients.The Company’s research and development department also modifies, refines, and expands the uses for existing products, withthe goal of further developing the market for the Company's products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        United's predecessor,United International Research, Inc. ("UIR"), was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus,United's Chairman and Director of Research until his death on April 9, 2009. On February 10, 1982, a merger took place betweenUIR and Guardian Chemical Corporation ("Guardian"), an affiliate of UIR, whereby Guardian was merged into UIR and thename was changed to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian, Inc. (New York) wasmerged with and into a newly formed Delaware corporation by the same name, United-Guardian, Inc., for the purpose of changing thedomicile of the Company to Delaware.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company hasa broad range of products, some of which are currently marketed and some of which are still in the research and development stage.Of the products being actively marketed, the two largest product lines are the Lubrajel        <sup>         ®        </sup>        line of cosmetic ingredientsand medical lubricants, which accounted for 57% of the Company's sales in 2020, and Renacidin        <sup>         ®        </sup>        Irrigation Solution(“Renacidin"), a pharmaceutical product that accounted for 36% of the Company's sales in 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Unless indicated otherwise,all references in this Annual Report to “sales” or “Sales” shall mean net sales. When changes are shownas percentages, the number is approximate and has been rounded from one decimal place to the nearest whole number.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (b)        <b>         <u>          Description of Business         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company manufacturesand markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It also conducts researchand development, primarily related to the development of new and unique cosmetic ingredients. The Company focuses on the developmentof products that fill unmet market needs, have unique properties, and use proprietary technology that it sometimes protects withpatents. Many of the Company's products are marketed through collaborative agreements with larger companies. The cosmetic ingredientsmanufactured by the Company are marketed to end users through the Company's worldwide network of marketing partners and distributors,and are currently used by many of the major manufacturers of cosmetic products. The Company sells products outright to its marketingpartners, Ex Works (EXW) the Company’s plant in Hauppauge, New York. Those marketing partners in turn resell those productsto their customers, who are typically the manufacturers and marketers of cosmetic and personal care products, and who in turn utilizethe Company’s products in their finished products. The products are not sold on a consignment basis, so unless a productis determined to be defective it is not returnable, except at the discretion of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company operatesin one business segment. The Company’s products are separated into four distinct product categories: cosmetic ingredients,pharmaceuticals, medical products, and industrial products. Each product category is marketed differently.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’scosmetic ingredients are currently marketed globally by five marketing partners, of which Ashland Specialty Ingredients (“ASI”),a business segment of Ashland, Inc., is the largest. ASI manufactures and markets globally an extensive line of personal care andpharmaceutical additives and various other specialty products. The Company’s cosmetic ingredients are sold directly to thosemarketing partners, which in turn resell those products to their customers for use in the formulation of one or more of the customers’personal care and cosmetic products. The Company’s non-pharmaceutical medical products (referred to hereinafter as the Company’s“medical products”) and its specialty industrial products are sold directly by the Company to marketers of finishedproducts or to the contract manufacturers utilized by those marketers. The Company’s pharmaceutical products are marketedprimarily through its dedicated Renacidin website and by internet advertising, and are sold to hospitals and pharmacies primarilythrough full-line drug wholesalers, which purchase the Company’s products outright for resale to their customers. The Companyalso sells a small quantity of pharmaceutical products directly to hospitals and pharmacies. The Company's products are sold undertrademarks or trade names owned by the Company, some of which are registered with the United States Patent and Trademark Officeas well as with comparable regulatory agencies in some foreign countries. The Company has a corporate website at www.u-g.com, anda specific website for Renacidin at www.renacidin.com.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          IMPACT OF THE CORONAVIRUS PANDEMIC         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        In March 2020, thespread of the coronavirus (COVID-19) began to cause disruptions among businesses and markets worldwide. On March 20, 2020, theGovernor of New York issued an executive order which closed non-essential businesses. The Company, as a manufacturer of pharmaceuticaland medical products, was considered an essential business, and continued to operate throughout the pandemic. When the spread ofthe coronavirus was at its worst in New York the Company modified its staffing schedule in order to decrease employee density asmuch as possible, with employees working 7 days a week on altered hours, and later on an every-other-week work schedule with limitedhours. Despite the reduced schedule the Company was able to maintain adequate production and shipping schedules, and was able tofill all orders on a timely basis. As things improved, the Company gradually increased its working hours and employee density untilit resumed its regular working schedule in June 2020. Throughout the pandemic the Company was able to maintain its full payroll,all employees received their full pay, and no employees were furloughed or dismissed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 4; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        While the Company’spharmaceutical sales have not been impacted by the coronavirus pandemic, sales of the Company’s cosmetic ingredients andmedical products have been significantly impacted, particularly in the second half of 2020. Sales of the Company’s cosmeticingredients in 2020 decreased by 33% compared with 2019. The decrease was primarily the result of lower sales to ASI, the Company’smarketing partner in China, and was caused primarily by factors related to the coronavirus, including (a) lower consumer demandin China for many of the products in which the Company’s products are used; (b) manufacturing disruptions in China resultingfrom the impact of the coronavirus on manufacturing facilities; and (c) excess inventory levels due to overstocking on the partof both the Company’s marketing partner for China as well as its sub-distributors in China. The overstocking was due to theuncertainty on the part of the marketing partner about being able to continue to get product from the Company during the pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        Because the Company’scosmetic ingredients are marketed in many different countries, it is difficult to project the future impact of the coronaviruspandemic on the Company’s global cosmetic ingredient sales, since the virus continues to impact different countries at differenttimes and to very different extents. The Company is hopeful that as vaccinations increase, the global economic situation will graduallyimprove. However, based on the current situation, as well as future projections by different analysts, the Company anticipatesthat the pandemic will continue to negatively impact sales of the Company’s cosmetic ingredients throughout most or all of2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        The Company also believesthat the coronavirus impacted sales to two of the Company’s four major medical product customers whose orders decreased in2020, and may have been a factor in the loss of a third (although the Company has not yet been able to confirm that as the reasonfor that lost business). Overall sales of the Company’s medical products decreased by 31% compared with the correspondingperiods in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        With the continuinguncertainty as to what the duration and future impact of the pandemic will be, the Company is unable to provide an accurate estimateor projection as to what the continuing impact of the coronavirus will be on the Company’s operations or its financial resultsin the future. However, as of the date of this report, the Company does not anticipate that the coronavirus pandemic will affectthe ability of the Company to obtain raw materials and maintain production. The Company has price protection on some but not allof its most important raw materials, has multiple sources for many of its raw materials, and has been able to maintain sufficientinventory and production levels to enable it to fulfill sales orders on a timely basis. The Company does not expect the carryingvalue of its assets or its liquidity to be impaired by the coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          PRODUCTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As stated above, theCompany operates in one business segment, and its product lines are separated into four distinct product categories:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COSMETIC INGREDIENTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL        </b>        <sup>         ®        </sup>        is an extensive line of water-based moisturizing and lubricating gel formulations that are used as ingredients in personal care(primarily cosmetic/skincare) products. In the personal care industry, they are used primarily as moisturizers and as bases forother personal care products, and can be found as an ingredient in skin creams, moisturizers, makeup, and body lotions. Includedin the many different formulations of Lubrajel are variations that use different types of preservatives, as well as some, like        <b>         Lubrajel PF        </b>        ,        <b>         Lubrajel Oil PF        </b>        , and        <b>         Lubrajel II XD PF        </b>        , which are all preservative-free.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 5; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL NATURAL        </b>        was thefirst product in a line of Lubrajel products for cosmetic use that are produced using only ingredients that are considered “natural”.This product, as well as the additional “natural” products under development (see “Development Activities”below) are based on natural polysaccharides, which contribute moisturization, emulsion stabilization, and emolliency to personalcare products, particularly creams and lotions. Ecocert, one of the global organizations authorized to certify natural and organicproducts, has certified that Lubrajel Natural complies with the Cosmetic Organic and Natural Standard (“COSMOS”), indicatingthat the product is suitable for use in natural and organic cosmetic products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL MARINE™        </b>        was the second product that the Company developed for its new line of “natural” cosmetic ingredients. It was formulatedusing naturally-derived polysaccharides, with some of the ingredients sourced from marine vegetation. This product was developedjointly with ASI, and for that reason is being marketed globally on an exclusive basis by ASI. Like the original Lubrajel Natural,this product has received COSMOS certification for use in natural and organic cosmetic products. It is being actively marketedby ASI, and while sales have not attained the levels that the Company had originally hoped for, the Company is still optimisticthat sales will increase as the interest in natural products in the marketplace continues.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Total sales of theCompany's cosmetic ingredients decreased by $2,102,737 (33%) for the year ended December 31, 2020 when compared with 2019, andaccounted for approximately 39% of total Company sales in 2020 compared with 47% in 2019. The decrease was due primarily to a decreasein sales of Lubrajel cosmetic ingredients to ASI for distribution in China, which the Company believes was due mainly to issuesrelated to the coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Each of the followingcosmetic ingredients accounted for less than 2% of the Company’s sales in 2020, listed in descending order of sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL II XD        </b>        is a versionof Lubrajel that was developed to be a direct replacement for one of the competitive products to Lubrajel. There is a paraben-freeversion of this product known as Lubrajel II XD Free, and the Company is currently developing a preservative-free version of theproduct.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         B-122        </b>        ™ is a powderedlubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrialproducts. The product acts as a binder, increases water-repellency and drop strength, and lowers the coefficient of friction inthe products in which they are used. Until 2021 the Company also had small sales of another powdered lubricant,        <b>         Lubraslide        </b>        ,but that product has now been discontinued due to the negative environmental impact of the PTFE that was one of its ingredients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         KLENSOFT        </b>        ™ is a surfactant(a surface-active agent, such as a soap or detergent) that can be used in shampoos, shower gels, makeup removers, and other cosmeticformulations. Klensoft sales have been highly variable due to the ordering patterns of the primary customers for the product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRASIL™ II SB        </b>        is a special formulation of Lubrajel in which silicone oil is incorporated into a Lubrajel base using proprietary technology thatenables the product to maintain much of the clarity of regular Lubrajel. The product has a silky feel and is water resistant whileat the same time providing moisturization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         ORCHID COMPLEX        </b>        ™is an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. It is an extract of fresh orchids modified bystabilizers, and is characterized by its excellent lubricity, spreadability, light feel, and emolliency. Because of its alcoholsolubility it may also be used in fragrance products, such as perfumes and toiletries. Its emolliency makes it an excellent additiveto shampoos, bath products and facial cleansers. It is also a superior emollient for sunscreens, vitamin creams, toners and skinserums.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company believesthat its ability to maintain and/or increase sales of its cosmetic ingredients will depend on (a) the ability and determinationof its marketing partners, especially its largest marketing partner, ASI, to continue to aggressively promote the Company’sproducts, particularly to new customers, and to find new marketing opportunities for those products; (b) the Company's successin developing new and innovative cosmetic ingredients, including new types of water-based moisturizers and lubricants; developingnew applications for existing products; and (c) the ability of the Company to compete with manufacturers of lower-cost competitorsto Lubrajel that have negatively impacted the sales of the Company’s cosmetic ingredients over the past few years. In particular,the Company has experienced significant pricing pressure from competitive products being marketed by some Asian manufacturers.These lower-cost competitive products are likely to continue to negatively impact the Company’s sales and profit marginson some of its products in certain geographic areas.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company believesthat there is still potential to expand the sales of its cosmetic ingredients through new product development, modifications tomake some of its current products more competitive, additional claim substantiation, and geographic expansion. The Company believesthat its strong brand identity, reliability, and reputation for supplying quality products will be advantageous in its effortsto compete with the growing number of lower-cost competitors, but that it will still be necessary to be more competitive with itsproduct pricing in certain geographic areas in order to maintain and grow its market share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          MEDICAL LUBRICANTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL RR        </b>        and        <b>         RC        </b>        are both water-based gels used primarily as lubricants for urinary catheters. They are special grades of Lubrajel that can withstandsterilization by gamma radiation, which is one of the methods of terminally sterilizing medical and hospital products. LubrajelRR was the original radiation resistant Lubrajel product. Lubrajel RC was developed as a lower-cost alternative to Lubrajel RRfor those customers who are in more cost-sensitive markets. Sales of Lubrajel RR increased in 2020 compared with 2019, and salesof Lubrajel RC. The Company believes that the decrease in sales of Lubrajel RC was primarily the result of a decrease in ordersfrom one of the Company’s customers that has been impacted by the coronavirus pandemic. The combined sales of both productsaccounted for 10% of the Company’s sales in 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL MG        </b>        is the originalform of Lubrajel, developed as a medical lubricant in the 1970s. It is used by many medical device manufacturers for lubricatingurinary catheters, pre-lubricated enema tips, and other medical devices. Sales for this product decreased in 2020 compared with2019 due to a decrease in sales to two of the Company’s larger customers for this product that are located in areas, suchas China, that were significantly impacted by the coronavirus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL LC and LUBRAJEL FA        </b>        are Lubrajel formulations that were developed for use in oral care applications. Sales of these products decreased in 2020 comparedwith 2019 primarily as the result of a decrease in orders from the Company’s primary customer, which the Company believeswas related to the coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         LUBRAJEL FLUID        </b>        is a verylow viscosity form of Lubrajel that was developed to provide superior lubrication in water-soluble products. It was specificallydeveloped, and is currently in limited use, as a replacement for silicone oils in pre-lubricated condoms. The Company has onlyone customer for this product, and sales of this product did not contribute significantly to the Company’s overall sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Sales of all of themedical grades of Lubrajel decreased by 31% in 2020 compared with 2019 and accounted for approximately 19% of the Company’ssales in 2020 compared with approximately 22% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          PHARMACEUTICALS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         RENACIDIN         <sup>          ®         </sup>        </b>        is a prescription drug product that is used primarily to prevent and to dissolve calcifications in urethral catheters and in theurinary bladder. It is currently marketed in a plastic 30 mL single-dose bottle. Sales of Renacidin increased by approximately12% in 2020 compared with 2019, and represented approximately 36% of total Company sales. The Company believes that the increasewas due to the Company’s increased marketing efforts for this product, including a dedicated website and expanded internetadvertising.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         CLORPACTIN        </b>        <sup>         ®        </sup>        <b>         WCS-90        </b>        is an antimicrobial product used primarily in urology to treat infections in the urinary bladder. It is also usedin surgery for treating a wide range of localized infections in the peritoneum (the lining of the abdominal cavity), as well asthe eye, ear, nose and throat, and sinuses. The product is a powder that is mixed with water by the end user and used as a solution.It is also a powerful disinfectant, fungicide, and deodorizer. Sales of Clorpactin have been very consistent from year-to-year,and in 2020 sales of Clorpactin represented approximately 6% of the Company’s sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’spharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) theproduct is damaged in shipping; or (c) they are outdated (but not more than one year after their expiration date, which is a returnpolicy that conforms to standard pharmaceutical industry practice).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          INDUSTRIAL PRODUCTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         DESELEX        </b>        ™ is a sequesteringand chelating agent that is used primarily as a replacement for phosphates in the manufacture of detergents. It also has some usein personal care products as a chelating agent in shampoos and body washes. Sales of this product decreased slightly in 2020 andrepresented less than 1% of Company sales. The decrease in sales was primarily due to a decrease in orders from the Company’sprimary customer for this product, which the Company believes was due to the impact of the coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         THOROCLENS        </b>        is a chlorine-basedindustrial cleanser manufactured and packaged by the Company for a small company in New England. Sales of this product increasedin 2020, but, as with Deselex, represented less than 1% of Company sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          DEVELOPMENT ACTIVITIES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In coordination with,and with input from, its marketing partners, the Company's research and development department develops products that are usedin many different industries, including the personal care (including cosmetic), pharmaceutical, medical, health care, and specialtychemical industries. These products are in various stages of development, some currently marketable and some in the very earlystages of development requiring a substantial amount of development work to bring them to market. Research is also being done onnew uses for currently marketed products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Prior to initiatingresearch and development work on a product the Company consults with its global marketing partners to determine the marketabilityof the product, including the potential market size and the most effective method of marketing the product. After that, the researchand development department will determine whether the product can be successfully developed, including (a) laboratory refinementsand adjustments to suit the intended uses of the product; (b) stability studies to determine the effective shelf life of the productand suitable storage and transportation conditions; and (c) laboratory efficacy tests to determine the effectiveness of the productunder different conditions. If development proves feasible, the Company will then determine whether production and sales costsmake it feasible to bring the product to market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If the initial developmentwork is successful, and the estimated costs of further development are acceptable to the Company, further development work to bringthe product to market will continue, including scaling up from laboratory production batches to pilot batches to full-scale productionbatches. In the case of drug products or medical devices, significant additional work would have to be done, including studiesto determine safety and effectiveness, preparation of an Investigational New Drug (IND) Application, and finally the filing ofan NDA. Because of the high cost of bringing new drugs or medical devices to market, as well as the Company’s limited resources,the Company does not currently have plans to develop any new drugs or medical devices, and intends to focus its research and developmentefforts on the development of new and innovative products for the personal care and medical (non-drug) markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        While there can beno assurance that any particular project will result in a new marketable product or a commercially successful product, the Companybelieves that a number of its development projects, including those discussed below, may have commercial potential if the Company'sdevelopment efforts are successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company's majorresearch focus is on the development of new and unique cosmetic ingredients. The following are some of the projects on which theCompany is currently working:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         LUBRAJEL OIL PF:        </b>        This product was developed as a result of the high demand for the Company’s very popular Lubrajel Oil. Unlike that product,this formulation is preservative-free, which enables formulators to use their own preservative systems without having to accountfor preservatives already incorporated into the product. This approach has been very successful with the Company’s LubrajelPF, its first preservative-free product, and the Company is hopeful that a preservative-free formulation of Lubrajel Oil will alsobe successful. The Company has launched this product exclusively with Ashland. Ashland initially launched the product in Asiain June 2020, and followed with a global launch in November. Based on the amount of customer interest, as well as the qualificationof the product for use by existing and new customers, Ashland has indicated that it considers this launch to be a success.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         LUBRAJEL II XD PF:        </b>        Like Lubrajel Oil PF, this product was developed to meet the continuing market demand for preservative-free products. Currentformulators are moving from conventional preservative systems to more natural methods of preservation. Eliminating the preservativesenables a formulator to choose the preservative system that is best for their final application. This product is ready for marketing,and it is anticipated that Ashland will have formally launched this product in early February 2021. The product has already beenqualified by some customers in the EMEA market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         LOWER-COST LUBRAJEL:        </b>        Based on feedback from its marketing partners, the Company believes that there could be significant market potential for aversion of Lubrajel for cosmetic use that can be produced and marketed at a lower cost than the current line of Lubrajel products.There are certain global markets that are not suitable for the current price points for Lubrajel, and the Company believes thatthe development of a lower-priced Lubrajel could open these new markets for the Company. The idea for a lower-cost Lubrajel hasbeen discussed and considered by the Company for a number of years, and the Company believes that the time is right to focus onthese development efforts. The goal is to develop a lower-cost product with similar benefits to some of the Company’s otherLubrajel cosmetic products, but which would not take away sales from those other products. The Company’s current developmentefforts for this product have focused on evaluating competitive products and comparing their attributes to those of the productwe are developing. This initial research will enable the Company to determine the best path forward in developing a product thatwill be competitive in price sensitive markets. The Company anticipates that this initial research will be completed in early 2021,and that product development will begin shortly thereafter.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         OIL/WAX HYDRATION:        </b>        The concept for this product is an anhydrous textured gel that can be added to the oil phase of a cosmetic formula. Like manyof the Company’s other “natural” products, this product has a high natural origin content based on ISO 16128,and, like the Company’s other natural products, is intended to be certified as a “natural” ingredient. A prototypeformula has been tested for sensory benefits. Before additional development work is conducted on this prototype we will be discussingthe marketability of the product with our distributors to determine appropriate product pricing and anticipated customer interest.A clear understanding of what pricing the market will support is necessary before determining the next steps in this project.        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         LUBRAJEL 24:        </b>        The purpose of this project is to develop a product with 24-hour hydration. While the Company’s current water-based moisturizingproducts provide excellent hydration, the goal is to build upon that to produce a product with superior hydration that will lasta full 24 hours. Prototypes have been developed, and hydration testing is scheduled for March 2021. The results of this testingwill determine the next steps in this project.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         LUBRAJEL OIL NATURAL:        </b>        Thisproduct was developed to be an addition to the Company’s “natural” line of products. It uses vegetable feedstock,and is based on polysaccharide chemistry. Modifications have been made over the past year to increase hydration and stabilize theemulsion. Like the Company’s other “natural” products, this product has been certified by Ecocert to comply withthe COSMOS standards for use in natural and organic cosmetic products. The Company has initially launched this product with itsUK marketing partner due to a specific interest they had in this product. The product has already been qualified for use by somecustomers in the UK, and the first commercial order was placed in January 2021. We will continue to work with our marketing partnersto gain feedback on this product, and pursue additional markets where we believe that this product could be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        It should be emphasizedthat some of the projects listed above are in the very early stages of research and development, and there can be no guaranteethat any particular development project will result in a marketable product or in significant sales if it is marketed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’sresearch and development expenses in 2020 were $451,208 compared with $397,391 in 2019. The Company expects its research and developmentexpenses in 2021 to be comparable to those of 2020. Any additional increase in development and/or production costs will dependon whether capital investments are required in order to continue development work on, or to manufacture, any of the new productsunder development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company requiresall employees and consultants who may receive confidential and proprietary information to agree in writing to keep such informationconfidential.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          TRADEMARKS AND PATENTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company stronglybelieves in protecting its intellectual property and intends, whenever reasonably possible and economically practical, to obtainpatents in connection with its product development program. The Company currently holds several trademarks relating to its products.In recent years the Company has relied more on trade secrets and proprietary formulations and manufacturing methods to protectits intellectual property rather than patents, since under current patent law the filing of a patent now provides detailed proprietaryinformation that can be copied by companies in other countries where enforcement would be difficult and expensive, such as in China.The Company believes that in many cases it is better to protect its intellectual property in other ways that do not require thedisclosure of proprietary information. All of the patents that had previously been issued to the Company have expired. The Companywill continue to file patent applications in situations where it believes that relying on trade secrets would be insufficient protection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 10; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The various trademarksand trade names owned or used by the Company in its business are of varying importance to the Company. The most significant trademarksare Lubrajel        <sup>         ®        </sup>        , Renacidin        <sup>         ®        </sup>        , and Clorpactin        <sup>         ®        </sup>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          DOMESTIC SALES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          COSMETIC INGREDIENTS         </u>        </b>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the United Statesthe Company's cosmetic ingredient products are marketed and distributed exclusively by ASI in accordance with a marketing agreemententered into in 1996 with its predecessor company, International Specialty Products (“ISP”). That agreement was forthe marketing of the Company’s cosmetic ingredients in North, Central, and South America. Since that time, this initial agreementhas been modified and expanded multiple times (see “Marketing Agreements” below), most recently in 2019 when Koreawas added to ASI’s marketing territory. ASI also has the exclusive right to market two of the Company’s products:        <b>         LubrajelMarine        </b>        , which was the second product in the Company’s Lubrajel Natural line of products; and        <b>         Lubrajel BA        </b>        , an oralcare product which was specifically developed for ASI in 2012 but which, to date, has not had significant sales. ASI also has anon-exclusive right to sell certain of the Company's other industrial and medical products. The current agreement with ASI automaticallyrenewed on January 1, 2020 and will automatically renew again on January 1, 2022 unless either party chooses to terminate, whichcan be done by giving 60 days’ notice prior to the then expiration date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Revenue from domesticsales of all Company products accounted for approximately 80% of the Company’s total sales in 2020, compared with 82% in2019. Domestic sales of cosmetic ingredients accounted for approximately 30% of total Company sales in 2020, compared with 40%in 2019. Sales to the Company’s largest marketing partner, ASI, accounted for approximately 29% of total Company sales in2020 and 39% of sales in 2019. It should be noted, however, that while all sales to ASI are considered domestic sales because allshipments to ASI are delivered to ASI in the U.S., a significant percentage of ASI’s purchases from the Company are ultimatelysold to foreign customers. Based on sales information provided to the Company by ASI, 68% of ASI’s sales in 2020 were tocustomers in foreign countries, compared with 75% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          PHARMACEUTICALS         </u>        </b>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’spharmaceutical products are marketed only in the United States, and are sold primarily through full-line drug wholesalers. Salesof those products accounted for approximately 41% of Company sales in 2020, compared with approximately 30% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020 and 2019,the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceuticalproduct. These programs include the Medicaid Drug Rebate Program (MDRP), Section 340B Drug Pricing Program (340B), Veterans AffairsFederal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs required the Companyto either sell its product at a discounted price, or, in the case of Medicaid, to pay a significant rebate to the various stateswhere Renacidin was being provided to Medicaid patients. The Company’s sales, as reported, are net of these rebates, someof which are estimated and are recorded in the same period that the revenue is recognized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a result ofthe overly burdensome nature of the Medicaid rebates it became clear to the Company in October 2020 that it was no longerprofitable for the Company to continue participating in the Medicaid or the 340B programs. As a result, on October 30, 2020,the Company informed the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and ServicesAdministration (HRSA) of its intention to terminate its Medicaid Drug Rebate Agreement and its 340B Drug Pricing Agreement,effective December 31, 2020. The Company will, however, continue to participate in the other government discount and rebateprograms, specifically the Veterans Affairs FSS Program and the Medicare Part D Coverage Gap Program (CGDP).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 11; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          MEDICAL PRODUCTS         </u>        </b>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’snon-pharmaceutical medical products, such as its catheter lubricants and oral care products, are sold directly by the Company tothe end users or to contract manufacturers utilized by the end users. These products are also are available for sale on a non-exclusivebasis by its marketing partners as well. Domestic sales of the Company’s medical products accounted for approximately 8%of the Company’s total sales in 2020, compared with 11% in 2019. Although all shipments of medical products to U.S. locationsare considered domestic sales, a percentage of those shipments are subsequently shipped by some customers to foreign manufacturingfacilities, which then produce finished products that are marketed globally.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          INDUSTRIAL PRODUCTS         </u>        </b>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Domestic sales of theCompany’s specialty industrial products accounted for less than 2% of Company sales in both 2020 and 2019. These productsare sold directly to end-user customers or their contract manufacturers, who incorporate these products into their finished products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="text-transform: uppercase">         <b>          <u>           FOREIGN          </u>         </b>        </font>        <b>         <u>          SALES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In 2020 and 2019, approximately20% and 18%, respectively, of the Company’s sales revenue was from foreign sources, and was derived from (a) sales of itscosmetic ingredients to the Company’s foreign marketing partners, which accounted for approximately 9% of Company sales in2020 and 7% in 2019, and (b) sales of some of the Company’s medical products directly to certain customers in foreign countries,which accounted for approximately 11% of Company sales in both 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because all shipmentsto the Company’s largest marketing partner, ASI, are delivered to ASI’s warehouses in the U.S., all sales to ASI areincluded in “Domestic Sales”, even though a significant percentage of ASI’s sales of the Company’s productsare to customers in foreign countries. Based on sales information provided to the Company by ASI, 68% of ASI’s sales of theCompany’s products in 2020 were to customers in foreign countries, compared with 75% in 2019. ASI’s largest foreignmarket in both 2020 and 2019 was China, which accounted for approximately 33% of ASI’s sales of Company products in 2020and 49% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Since the Company sellsits products in U.S. Dollars, the Company’s selling prices are not affected by fluctuations in foreign currency exchangerates, except to the extent that a stronger dollar compared with foreign currencies can make the Company’s products lesscompetitive in foreign markets, sometimes requiring the Company to adjust its prices in order to be more competitive. In recentyears, sales have been negatively impacted by the strength of the U.S. Dollar relative to other currencies, particularly the Euro,which has resulted in some of the Company’s products being more price sensitive than they had been in the past. It has alsoenabled some of the Company’s competitors to take some market share from the Company in those markets. As a result of theweakening dollar in 2020, the Company’s products became a little more competitive than they have been over the past few years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 12; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          SALES AND MARKETING         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company marketsits products through marketing partners and distributors, promotion on the Company’s websites, and by internet advertising,and has some direct sales to customers as well. The cosmetic ingredients are sold outright (not on consignment) to the Company’smarketing partners, which in turn market and resell the products to cosmetic and other personal care product manufacturers foruse in the formulation of one or more of their products. The pharmaceutical products are sold in the United States primarily todrug wholesalers, which in turn distribute and resell those products to drug stores, hospitals, physicians, long-term care facilities,the U.S. Department of Veterans Affairs, and other government agencies. The medical and specialty industrial products are soldby the Company directly to the end users. The industrial products are older products that have limited marketability but are stillbeing sold to some long-time customers. They are not actively marketed but are available for sale to any new customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          MARKETING AGREEMENTS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has a writtenmarketing agreement only with ASI. All other marketing arrangements are subject to cancellation at any time by either the Companyor the marketing partner. The marketing agreement with ASI gives it exclusive foreign marketing rights with the exception of thefollowing territories, where the Company's other marketing partners have exclusive marketing rights: the United Kingdom (by TheAzelis Group); France (by Sederma SAS, a subsidiary of Croda International Plc.); Italy (by Safic-Alcan); and Switzerland (by AzelisCosmetics GmbH.).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        That agreement setforth provisions under which ISP/ASI would market and distribute the Company's cosmetic ingredients, as well as some medical andspecialty industrial products, in certain parts of Europe, Asia, Australia, and Africa. In 1996, the parties entered into anotheragreement, which extended ASI’s distribution rights to the United States, Canada, Mexico, and Central and South America,and in December 2019 the marketing rights in Korea were transferred to ASI from the Company’s previous distributor for Korea.In July 2000, December 2002, December 2005, May 2010, November 2012, and November 2013 the parties entered into additional agreementsthat modified, extended, and consolidated the 1994 and 1996 agreements, and provided for automatic two-year renewals of ASI’smarketing rights unless either party terminated the arrangement upon 60 days’ notice. The agreement automatically renewedon January 1, 2012, 2014, 2016, 2018, and 2020 for additional two-year terms. The current contract ends on December 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company believesthat in the event ASI were to cease marketing the Company's products alternative arrangements could be made with one of the otherglobal marketers of cosmetic ingredients to continue to supply products to customers currently using the Company's products, withoutany significant interruption of sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          RAW MATERIALS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The principal raw materialsused by the Company consist of common industrial organic and inorganic chemicals. Most of these materials are available in amplesupply from numerous sources. The Company has six major raw material vendors that together accounted for approximately 88% of theraw material purchases by the Company in 2020 and 84% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          INVENTORIES, RETURNS, and ALLOWANCES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        It is important forthe Company to maintain moderate inventory levels of certain of its finished goods in order to fulfill purchase orders in a timelymanner. Historically, sufficient inventory levels, returns, and allowances have not been a significant factor in the Company'sbusiness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 13; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          BACKLOG         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company currentlydoes not have any significant backlog of orders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          SEASONALITY         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Due to the nature ofthe Company's business and the types of products it markets, it is not subject to any significant seasonal fluctuations in sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          CUSTOMERS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’scosmetic ingredients are currently marketed and sold globally by five marketing partners. Those marketing partners in turn marketand distribute those products to their customers. Although the Company depends on those marketing partners for the marketing anddistribution of its cosmetic ingredients, it is confident that if any of its marketing partners were to decide not to sell theCompany’s products, or if the Company chose to replace one or more of those marketing partners, it would be able to put inplace new marketing agreements to service its customers in all the geographic areas affected. If necessary, the Company would alsobe able to sell directly to the end users of its products until such time as a new marketing partner is put in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’spharmaceutical products are sold to, and distributed by, full-line drug wholesalers throughout the United States. Its medical andspecialty industrial products are sold directly by the Company to the end users of those products or, in some cases, to contractmanufacturers used by some of those end users.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          COMPETITION         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has someproducts or processes that are either proprietary or have some unique characteristics. Its Lubrajel line of products is well knownglobally and has a long-standing reputation for high quality. The Company believes that these characteristics will be advantageousto the Company in its continuing efforts to compete effectively with other companies marketing similar products. The pharmaceutical,health care, and cosmetic industries are all highly competitive, and during 2020 the Company experienced a high level of competitionfor its cosmetic ingredients both in the U.S. and in foreign markets. Unlike in 2019, in 2020 the value of the U.S. dollar declinedrelative to some other foreign currencies, in particular the Euro, which made the Company’s products a little more competitivein those markets than it had been in recent years. Despite the more favorable currency situation, the Company believes that therewill continue to be significant competition for its products, especially from Asian competitors, and the Company intends to continueto work closely with its marketing partners to remain as competitive as possible. The Company is aware that there are other domesticand foreign companies that are engaged in the same or similar areas of research as those in which the Company is engaged, someof which have substantially greater financial, research, manpower, marketing and distribution resources than the Company. In addition,there are many large, integrated and established companies that have greater capacity than the Company to develop and to commercializethe types of products upon which the Company's research and development programs are based. The Company intends to continue tofocus its research efforts on the development of new and innovative products for which there is not the same competitive situationas there is for some of the Company’s older products, and it is optimistic that the development of unique products, includingproducts made exclusively with natural ingredients, will enable it to continue to compete in a market in which competition hasbecome more of a factor than it had been in the past.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 14; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          ISO 9001:2015 REGISTRATION         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On July 23, 2018, theCompany was certified by Underwriters Laboratories, Inc. to be in compliance with the latest ISO standard, ISO 9001:2015, indicatingthat the Company's documented procedures and overall operations had attained the high level of quality needed to comply with thiscurrent ISO certification level. From October 2009 to July 2018, the Company had been registered under the ISO 9001:2008 standard;from December 2003 to October 2009, the Company had been registered under the ISO 9001:2000 standard; and between November 1998and December 2003 the Company had been registered under the ISO 9002 standard. The Company has been in continuous compliance withISO standards since November 1998.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          GOVERNMENT REGULATION         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Regulation by governmentalauthorities in the United States and other countries is a significant factor in the manufacturing and marketing of many of theCompany's products. The Company and many of the Company's products are subject to certain government regulations. Some productsdeveloped and sold by the Company in the United States may require approval from federal regulatory agencies, such as the U.S.Food &amp; Administration (“FDA”), as well as state regulatory agencies. Some products developed and sold by theCompany outside the United States may require approval from foreign regulatory agencies. Although the Company does not currentlymarket any medical devices, if it were to do so a 510(k) pre-market notification to the FDA would be required to demonstrate thatthe device is at least as safe and effective as a legally marketed device. The Company would then need to receive clearance fromthe FDA prior to marketing the device. While the Company does not have any plans to develop new pharmaceutical products, if itdecided to do so any new drug product would require clinical evaluation under an Investigational New Drug Application, and thesubsequent submission to the FDA of a New Drug Application.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company is requiredto comply with all pertinent current Good Manufacturing Practices of the FDA for medical devices and drugs. Accordingly, the regulationsto which the Company and certain of its products may be subject, and any changes with respect thereto, may materially affect theCompany's ability to produce and market new products developed by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company's presentand future activities are, and will likely continue to be, subject to varying degrees of additional regulation under the OccupationalSafety and Health Act, Environmental Protection Act, import, export and customs regulations, and other present and possible futureforeign, federal, state and local regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Portions of the Company'soperating expenses are directly attributable to complying with federal, state, and local environmental statutes and regulations.In 2020 and 2019, the Company incurred approximately $13,000 and $39,000, respectively, in federal, state, and local environmentallaw compliance expenses. There was no material financial or other impact on the Company as a result of compliance with environmentallaws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          EMPLOYEES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company presentlyhas 25 employees, 4 of whom serve in an executive capacity, 16 in research, quality control and manufacturing, 3 in maintenanceand construction, and 2 in office and administrative support services. Of the total number of employees, 22 are full time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 1A.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Risk Factors.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information tobe reported under this item is not required of smaller reporting companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 15; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 1B.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Unresolved Staff Comments.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information tobe reported under this item is not required of smaller reporting companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 2.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Properties.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company maintainsits principal office and factory, and conducts its research, at a 50,000 square foot facility on a 2.7-acre parcel at 230 MarcusBoulevard, Hauppauge, New York 11788, which the Company owns. Of the 50,000 square feet, approximately 30,000 square feet is manufacturingspace, 15,000 square feet is warehouse space, and 5,000 square feet is office and laboratory space. The Company has fully developedthe 2.7 acres, and fully utilizes the building occupying the land. The Company believes that the aforementioned property is adequatefor its immediately foreseeable needs. The property is presently unencumbered and, in the Company’s opinion, is adequatelyinsured.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 3.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Legal Proceedings.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 4.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Mine Safety Disclosures.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PART II        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 5.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Market Information         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Common Stock ofthe Company has traded on the NASDAQ Global Market since March 16, 2009, under the symbol "UG". From December 1, 2008through March 13, 2009, following the merger of the American Stock Exchange with the New York Stock Exchange, the Company's CommonStock was traded on the NYSE Amex Stock Exchange under the same symbol. Prior to December 1, 2008, its stock traded on the AmericanStock Exchange under the same symbol.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Holders of Record         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of March 1, 2021,there were 395 holders of record of Common Stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Cash Dividends         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On May 20, 2020, theCompany’s Board of Directors declared a semi-annual cash dividend of $0.42 per share, which was paid on June 17, 2020 toall stockholders of record as of June 3, 2020. On November 18, 2020, the Company’s Board of Directors declared a semi-annualcash dividend of $0.36 per share which was paid on December 8, 2020 to all stockholders of record as of December 1, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 16; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On May 15, 2019, theCompany’s Board of Directors declared a semi-annual cash dividend of $0.55 per share, which was paid on June 14, 2019 toall stockholders of record as of May 31, 2019. On November 20, 2019, the Company’s Board of Directors declared a semi-annualcash dividend of $0.55 per share, which was paid on December 10, 2019 to all stockholders of record as of December 3, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 6.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Selected Financial Data.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company is notproviding information responsive to this Item as it is choosing to voluntary comply with the revisions to Item 6 of Form 10-K containedin SEC Release No. 33-10890, which eliminated the disclosure requirements contained in Item 301 of Regulation S-K. Prior to theissuance of SEC Release 33-10890 the Company was not required to provide the information because the Company was a small businessissuer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 1in">           <b>            Item 7.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Management's Discussion and Analysis of Financial Condition and Results of Operations.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Impact of the Coronavirus Pandemic         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In March 2020, thespread of the coronavirus (COVID-19) began to cause disruptions among businesses and markets worldwide. On March 20, 2020, theGovernor of New York issued an executive order which closed non-essential businesses. The Company, as a manufacturer of pharmaceuticaland medical products, was considered an essential business, and continued to operate throughout the pandemic. When the spread ofthe coronavirus was at its worst in New York, the Company modified its staffing schedule in order to decrease employee densityas much as possible, with employees working 7 days a week on altered hours, and later on an every-other-week work schedule withlimited hours. Despite the reduced schedule the Company was able to maintain adequate production and shipping schedules and wasable to fill all orders on a timely basis. As things improved, the Company gradually increased its working hours and employee densityuntil it resumed its regular working schedule in June 2020. Throughout the pandemic the Company was able to maintain its full payroll,all employees received their full pay, and no employees were furloughed or dismissed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        While sales of theCompany’s pharmaceutical products have not been impacted by the coronavirus pandemic, sales of the Company’s cosmeticingredients and medical products were significantly impacted, particularly in the second half of 2020. Sales of the Company’scosmetic ingredients in 2020 decreased by 33% compared with 2019. The decrease was primarily the result of lower sales to ASI,the Company’s marketing partner in China, and was caused primarily by factors related to the coronavirus, including (a) lowerconsumer demand in China for many of the products in which the Company’s products are used; (b) manufacturing disruptionsin China resulting from the impact of the coronavirus on manufacturing facilities; and (c) excess inventory levels due to overstockingon the part of both the Company’s marketing partner for China as well its sub-distributors in China. The overstocking wasdue to the uncertainty on the part of the marketing partner about being able to continue to get product from the Company duringthe pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Since the Company’scosmetic ingredients are marketed in many different countries, it is difficult to project the future impact of the coronaviruspandemic on the Company’s global cosmetic ingredient sales, since the virus continues to impact different countries at differenttimes and to very different extents. The Company is hopeful that as vaccinations increase, the global economic situation will graduallyimprove. However, based on the current situation, as well as future projections by different analysts, the Company anticipatesthat the pandemic will continue to negatively impact sales of the Company’s cosmetic ingredients throughout most or all of2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 17; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company also believesthat the coronavirus impacted sales to two of the Company’s four major medical product customers whose orders decreased in2020, and may have been a factor in the loss of a third (although the Company has not yet been able to confirm that as the reasonfor that lost business). Overall sales of the Company’s medical products decreased by 31% compared with the correspondingperiods in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        With the continuinguncertainty as to what the duration and future impact of the pandemic will be, the Company is unable to provide an accurate estimateor projection as to what the continuing impact of the coronavirus will be on the Company’s operations or its financial resultsin the future. However, as of the date of this report, the Company does not anticipate that the coronavirus pandemic will affectthe ability of the Company to obtain raw materials and maintain production. The Company has price protection on some but not allof its most important raw materials, has multiple sources for many of its raw materials, and has been able to maintain sufficientinventory and production levels to enable it to fulfill sales orders on a timely basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Critical Accounting Policies         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’sfinancial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America(“US GAAP”). Preparation of financial statements requires the Company to make estimates and assumptions affecting thereported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities. The Companyuses its historical experience and other relevant factors when developing its estimates and assumptions, which are continuallyevaluated. Note A, Nature of Business and Summary of Significant Accounting Policies, of the Notes to Financial Statements, includedin Item 8, Financial Statements and Supplementary Data, of this Annual Report includes a discussion of the Company’s significantaccounting policies. The following accounting policies are those that the Company considers critical to an understanding of thefinancial statements because their application places the most significant demands on the Company’s judgment. The Company’sfinancial results might have been different if other assumptions had been used or other conditions had prevailed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          Marketable Securities         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’smarketable securities include investments in equity and fixed income mutual funds, and U.S. Government securities. The Company’smarketable equity securities are reported at fair value with the related unrealized and realized gains and losses included innet income. U.S Treasury Bills are considered debt securities and realized gains or losses, if any, are reported in other comprehensiveincome. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates itsinvestments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extentto which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intentto hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company recordsan impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of thesecurities and the decline in value is determined to be other-than-temporary. During 2020 and 2019, the Company did not recordan impairment charge regarding its investment in marketable securities because management believes, based on its evaluation ofthe circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 18; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          Revenue Recognition         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company recordsrevenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognizedwhen a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be receivedin exchange for those goods or services. The Company’s principal source of revenue is product sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’ssales, as reported, are subject to a variety of deductions, which generally are estimated and recorded in the same period thatthe revenues are recognized. Such variable consideration, primarily related to the sale of the Company’s pharmaceutical products,includes chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with participationin Medicare and Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimatesof the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductionson sales for a reporting period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020 and 2019,the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceuticalproduct. These programs include the Medicaid Drug Rebate Program (MDRP), Section 340B Drug Pricing Program (340B), Veterans AffairsFederal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs required the Companyto either sell its product at a discounted price, or, in the case of Medicaid, to pay a significant rebate to the various stateswhere Renacidin is provided to Medicaid patients. The Company’s sales, as reported, are net of these rebates, some of whichare estimated and are recorded in the same period that the revenue is recognized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a result ofthe overly burdensome nature of the Medicaid rebates it became clear to the Company in October 2020 that it was no longerprofitable for the Company to continue participating in the Medicaid or the 340B programs. As a result, on October 30, 2020,the Company informed the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and ServicesAdministration (HRSA) of its intention to terminate its Medicaid Drug Rebate Agreement and its 340B Drug Pricing Agreement,effective December 31, 2020. The Company will, however, continue to participate in the other government discount and rebateprograms, specifically the Veterans Affairs FSS Program and the Medicare Part D Coverage Gap Program (CGDP).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As long as a validpurchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenuefrom sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied.The Company’s products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the riskof loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceuticalmedical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow thereturn of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless(a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than oneyear after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Companyestimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company does notmake sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingentupon the customer being able to sell the goods to a third party.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Any allowances forreturns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined basedon historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimatedallowances and actual activity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 19; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The timing betweenrecognition of revenue for product sales and the receipt of payment is not significant. Due to COVID-19, the Company experiencedminor delays in receiving payments from certain customers that were impacted by the pandemic; however, the negative impact of thosedelayed payments was not significant. The Company’s standard credit terms, which vary depending on the customer, range between30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivablesand provides allowances for any receivables for which collection has become doubtful. As of December 31, 2020 and December 31,2019, the allowance for doubtful accounts receivable was $14,017 and $21,178, respectively. Prompt-pay discounts are offered tosome customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they aretaken.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has distributionagreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-relatedfees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          Accounts ReceivableAllowance         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company performsongoing credit evaluations of the Company’s customers and adjusts credit limits, as determined by a review of current creditinformation. The Company continuously monitors collection and payments from customers and maintains an allowance for doubtful accountsbased upon historical experience, the Company’s anticipation of uncollectible accounts receivable and any specific customercollection issues that have been identified. While the Company’s credit losses have historically been low and within expectations,the Company may not continue to experience the same credit loss rates that have historically been attained. The receivables arehighly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position,or willingness to pay timely, or at all, of any one of the Company’s significant customers would have a significant impacton the Company’s results of operations and cash flows. As mentioned above, the Company has not experienced significant issueswith the collection of its accounts receivable balances due to the COVID-19 pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          Inventory ValuationAllowance         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In conjunction withthe Company’s ongoing analysis of inventory valuation, management constantly monitors projected demand on a product-by-productbasis. Based on these projections, management evaluates the levels of write-downs required for inventory on hand and inventoryon order from contract manufacturers. Although the Company believes that it has been reasonably successful in identifying write-downsin a timely manner, sudden changes in buying patterns from customers, either due to a shift in product interest and/or a completepull back from their expected order levels, may result in the recognition of larger-than-anticipated write-downs. The Company hasperformed an evaluation of its inventory on hand as of the date of this report and believes the reserve is adequate to cover anyslow-moving or obsolete inventory. The Company does not believe the value of its finished products, work in process or raw materialinventories have been adversely affected by the coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Results of Operations         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Year ended December 31, 2020 compared withthe year ended December 31, 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <u>          Sales         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Sales decreased 19%from $13,599,084 in 2019 to $10,986,081 in 2020. The decrease was due primarily to decreases in sales of the Company’s cosmeticproducts and non-pharmaceutical medical products. Those decreases were partially offset by an increase in sales of the Company’spharmaceutical products, primarily Renacidin.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The decrease in sales was the result ofthe following specific changes in sales in the different product categories:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18pt">          </td>          <td style="width: 19.45pt">           <font style="font-size: 10pt">            (a)           </font>          </td>          <td style="text-align: justify">           <b>            <u>             Cosmetic Ingredients            </u>           </b>           <font style="font-size: 10pt">            :           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">        Sales of the Company's cosmeticingredients decreased from $6,377,323 in 2019 to $4,274,586 in 2020. The decrease was attributable primarily to a decrease in salesof the Company’s Lubrajel line of products to ASI, the Company’s largest marketing partner, whose purchases decreasedby 40% in 2020. Aggregate sales to the Company’s four other marketing partners increased from $914,690 in 2019 to $992,951in 2020. That increase was primarily attributable to Company’s marketing partner in the UK, whose sales increased from $361,156in 2019 to $445,402 in 2020. There was also a small increase in sales of the Company’s cosmetic ingredients to three otherdirect customers of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">        In addition to the above changesin marketing partner sales, as a result of the termination in December 2019 of the Company’s marketing agreement with itsformer marketing partner in Korea, there were no sales to that former marketing partner in 2020, compared with sales of $88,447in 2019. Since December 2019 the Company’s marketing efforts in Korea are being handled by ASI.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">        The decrease in sales to ASIwas due to a number of factors, the principal one being the impact of the coronavirus pandemic, which significantly impacted ASI’ssales of the Company’s products in China. The decrease in ASI sales in China was the result of a number of factors, including(a) lower consumer demand in China for many of the products in which the Company’s products are used; (b) manufacturing disruptionsin China resulting from the impact of the coronavirus on manufacturing facilities; and (c) excess inventory levels of the Company’sproducts resulting from overstocking on the part of both the Company’s marketing partner for China as well as its sub-distributorsin China, due to the uncertainty of being able to restock product during the pandemic. Since the Company’s cosmetic ingredientsare marketed globally by its marketing partners in many different countries, and since the virus continues to impact countriesat different times and to very different extents, it is difficult to project the future impact of the coronavirus pandemic on theCompany’s global cosmetic ingredient sales. Until the global crisis passes it is likely that there will continue to be anegative impact on the Company’s sales of its cosmetic ingredients, as well as, to a lesser extent, its non-pharmaceuticalmedical products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">        Although a significant percentageof ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financialreporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of thoseproducts are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 68%of ASI’s sales in 2020 were to customers in foreign countries, compared to 75% in 2019. ASI’s largest foreign marketin both 2020 and 2019 was China, which accounted for approximately 33% of ASI’s sales in 2020 and 49% of sales in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.45pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        There continues to be globalcompetition from Asian and European competitors selling products that are competitive with those sold by the Company and whichare marketed at lower prices than those produced by the Company. The weakening of the U.S. dollar relative to the Euro in 2020made the Company’s products a little more competitive in 2020 than they had been in the past few years when the dollar hadcontinued to strengthen against the Euro. The Company continues to work closely with its marketing partners to price its productsas competitively as possible and, when appropriate, to offer additional volume discounts and more aggressive pricing in order tomaintain and increase sales and bring in new customers. However, the Company expects the European market to remain very competitivebased on the continuing competition from lower-cost competitors, and for that reason it is concentrating its R&amp;D efforts ondeveloping new and unique products that these other companies do not have. The Company expects to introduce several such productsduring 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 21; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18pt">          </td>          <td style="width: 19.45pt">           <font style="font-size: 10pt">            (b)           </font>          </td>          <td style="text-align: justify">           <b>            <u>             Pharmaceuticals            </u>           </b>           <font style="font-size: 10pt">            :           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">        Because there are fees, rebates,and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin, discussion ofthe Company’s pharmaceutical sales includes references to both        <i>         gross sales        </i>        (before fees, rebates and allowances) and        <i>         net sales        </i>        (after fees, rebates and allowances).        <i>         Net        </i>        sales of the Company’s two pharmaceutical products, Renacidinand Clorpactin, together increased from $4,091,817 in 2019 to $4,519,052 in 2020, with Renacidin accounting for most of the increase.        <i>         Gross        </i>        sales of Renacidin increased from $4,635,019 in 2019 to $5,347,827 in 2020, while        <i>         gross        </i>        sales of Clorpactinincreased from $603,209 in 2019 to $611,878 in 2020. The Company believes that much of the increase in Renacidin sales was dueto increased awareness of the product by both patients, caregivers, and physicians, which the Company believes was the result ofthe Company’s internet advertising campaign, along with its dedicated Renacidin.com website. The Company intends to continuethese internet marketing efforts during 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">        As a result of the increasein sales of the Company’s pharmaceutical products, there was a commensurate increase in the allowances related to the salesof those products, including distribution fees, chargebacks on VA sales, Medicaid and Medicare rebates, and outdated material returns.Those fees, rebates, chargebacks, and other allowances increase proportionally as sales of the Company’s pharmaceutical productsincrease, and in 2020 the allowances related to pharmaceutical sales increased by $294,244 (26%) compared with 2019, primarilydue to the increase in Renacidin sales.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18pt">          </td>          <td style="width: 19.5pt">           <font style="font-size: 10pt">            (c)           </font>          </td>          <td style="text-align: justify">           <b>            <u>             Medical (non-pharmaceutical) products            </u>           </b>           <font style="font-size: 10pt">            :           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">        Sales of the Company’smedical products decreased from $2,968,806 in 2019 to $2,052,961 in 2020. Approximately 37% of that decrease was due to the lossof one of the Company’s four major medical product customers. One of the other customers is located in China, and the Companybelieves that the decrease in orders from that customer, as well as from one of its other major medical product customers not inChina, was related to the impact of the coronavirus pandemic. The Company is hopeful that as the global markets begin to recoverfrom the pandemic, orders from those affected customers will gradually increase.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18pt">          </td>          <td style="width: 19.5pt">           (d)          </td>          <td style="text-align: justify">           <b>            <u>             Industrial and other products:            </u>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">        Sales of the Company's industrialproducts, as well as other miscellaneous products, decreased from $161,138 in 2019 to $139,482 in 2020. The decrease was primarilydue to a decrease in sales to two of the Company’s industrial product customers, which operate in areas whose operationswere negatively impacted by the Coronavirus pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.5pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        <b>         <u>          Gross Profit on Sales         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Gross profit on saleswas 56% in 2020 compared with 58% in 2019. The decrease was due to the increased sales of Renacidin in 2020 compared with 2019,combined with the decrease in sales of the Company’s Lubrajel line of products, which carry a higher profit margin. Renacidincarries a lower gross profit margin than the Company’s other products due to the contract manufacturing costs connected withthe manufacture of the product, as well as the rebates, discounts and allowances associated with it. In 2020, Renacidin represented36% of the Company’s gross sales compared with 26% in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 22; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        <b>         <u>          Operating Expenses         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Operating expensesdecreased from $2,148,375 in 2019 to $2,026,368 in 2020. The decrease was mainly attributable to decreases in payroll, payrollrelated expenses, and employee fringe benefits. The Company was able to reduce these expenses during 2020 due to a lower employeehead count. The Company anticipates that operating expenses will remain relatively consistent for 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        <b>         <u>          Research and DevelopmentExpenses         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Research and developmentexpenses increased from $397,391 in 2019 to $451,208 in 2020. The increase was primarily related to an increase in payroll andpayroll related expenses and an increase in depreciation expense of R&amp;D equipment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        <b>         <u>          Investment Income         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Investment income increasedfrom $203,329 in 2019 to $226,245 in 2020. The increase was due to an increase in dividend income from both stock and bond mutualfunds. In early 2020, the Company began to shift its investment strategy from lower-yielding U.S. Treasury Bills towards shortand intermediate-term bond funds that were yielding higher returns. During 2019, the Company’s investment portfolio was moreheavily weighted in U.S. Treasury Bills, which yielded interest income that was less than the dividend income recognized in 2020from the Company’s stock and bond mutual funds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">        <b>         <u>          Net Gain on MarketableSecurities         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The net gain on marketablesecurities decreased from $431,076 in 2019 to $298,585 in 2020. The decrease was primarily due to the Company recognizing lowerunrealized gains on its stock and bond mutual funds compared with the same period in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Provision forIncome Taxes         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The provision for incometaxes decreased from $1,268,659 in 2019 to $856,022 in 2020. This decrease was due to a decrease in income before taxes. The Company’seffective income tax rate was 20.6% in 2020 and 21.1% in 2019. The Company’s effective income tax rate in 2020 was slightlylower than in 2019 due to higher research and development tax credits in 2020 compared with 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <u>          Liquidity and Capital Resources         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Working capital decreasedfrom $10,224,222 at December 31, 2019 to $9,832,326 at December 31, 2020. The current ratio decreased from 8.6 to 1 at December31, 2019 to 8.0 to 1 at December 31, 2020. The decrease in working capital was mainly due to decreases in cash and accounts receivableand an increase in accrued expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Accounts receivable(net of allowance for doubtful accounts) as of December 31, 2020 decreased from $2,098,411 in 2019 to $1,387,698 in 2020. The decreasein accounts receivable was due to the decrease in sales the Company experienced during 2020 due the coronavirus pandemic. The receivablesturnover, or “Days Sales Outstanding”, for 2020 was 58 days, compared with 51 days in 2019. The increase was mainlythe result of the Company experiencing minor delays in receiving payments from some customers during 2020 due to the pandemic.The Company’s allowance for doubtful accounts receivable decreased from $21,178 in 2019 to $14,017 in 2020, and the Companybelieves that the net balance of its accounts receivable as of December 31, 2020 was, and continues to be, fully collectible.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 23; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company generatedcash from operations of $3,594,240 in 2020 compared with $4,476,111 in 2019. The decrease in 2020 was primarily due to a decreasein net income in 2020 compared with 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Net cash provided byinvesting activities was $1,071,987 for the year ended December 31, 2019 compared with net cash used in investing activities of$468,676 for the year ended December 31, 2020. This decrease in net cash provided by investing activities was mainly due to theexecution of the Company’s strategy to purchase additional short and intermediate-term bond mutual funds in 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Net cash used in financingactivities was $3,582,431 and $5,049,922 during the years ended December 31, 2020 and 2019, respectively. The decrease was dueto the payment of lower dividends in 2020 compared with 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company believesthat its working capital is sufficient to support its operating requirements for the next fiscal year. The Company's long-termliquidity position will be dependent upon its ability to generate sufficient cash flow from profitable operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has nomaterial commitments for future capital expenditures and no material cash requirements of immediate concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has nooff balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financialcondition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capitalresources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On March 27, 2020,the coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act containsa provision known as the Employee Retention Credit (“ERC”), a refundable payroll tax credit for qualified wages paidto retained full-time employees between March 13, 2020 and December 31, 2020. The Consolidations Appropriations Act (CAA), signedinto law on December 27, 2020, significantly modified and expanded the provisions of the ERC to include wages paid in the firsthalf of 2021. The Company has determined that it has qualified for this credit in the first quarter of 2021 and anticipates utilizingbenefits under this act to aid its liquidity position. For 2021, the ERC provides employers a refundable federal tax credit equalto 70% of the first $10,000 of qualified wages and benefits paid to retained employees between January 1, 2021 and June 30, 2021.Credits may be claimed immediately by reducing payroll taxes sent to the Internal Revenue Service. To the extent that the creditexceeds employment withholdings, the employer may request a refund of prior taxes paid.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          New AccountingPronouncements         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">        See Note"A" to the financial statements regarding new accounting pronouncements, which note is incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 7A.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Quantitative and Qualitative Disclosures about Market Risk.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information tobe reported under this item is not required of smaller reporting companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 8.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Financial Statements and Supplementary Data.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Annexed hereto startingon page F-1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 24; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 9.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 9A.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Controls and Procedures.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        (a)        <b>         <u>          Evaluation of Disclosure Controlsand Procedures         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’smanagement, with the participation of the Company’s Principal Executive Officer and Principal Financial Officer, has evaluatedthe design, operation, and effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e)and 15d-15(e) of the Exchange Act as of December 31, 2020. On the basis of that evaluation, management concluded thatthe Company’s disclosure controls and procedures are designed to be, and are, effective at providing reasonable assurancethat the information required to be disclosed in reports filed or submitted pursuant to the Exchange Act is recorded, processed,summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulatedand communicated to management, including its Principal Executive Officer and Principal Financial Officer as appropriate, to allowtimely decisions regarding required disclosure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        (b)        <b>         <u>          Management’sReport on Internal Control over Financial Reporting         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Management is responsiblefor establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f).The Company’s internal control system is designed to provide reasonable assurance to management and to the Company’sBoard of Directors regarding the preparation and fair presentation of published financial statements. Under the supervision andwith the participation of management, including the Company’s Principal Executive Officer and Principal Financial Officer,management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting basedon the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the TreadwayCommission (COSO 2013). Based on management’s evaluation under the framework in Internal Control—Integrated Framework,management concluded that the Company’s internal control over financial reporting was effective as of December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This Annual Reportdoes not include an attestation report of the Company’s registered public accounting firm regarding internal control overfinancial reporting. Since the Company is a non-accelerated filer, management’s report is not subject to attestation by theCompany's registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. As a result,this Annual Report contains only management’s report on internal controls.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        (c)        <b>         <u>          Changesin Internal Control over Financial Reporting         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There were no changesin the Company’s internal control over financial reporting in the fourth quarter of 2020 that materially affected, or wouldbe reasonably likely to materially affect, the Company’s internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        (d)        <b>         <u>          Limitationsof the Effectiveness of Internal Controls         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The effectiveness ofthe Company’s system of disclosure controls and procedures and internal control over financial reporting is subject to certainlimitations, including the exercise of judgment in designing, implementing and evaluating the control system, the assumptions usedin identifying the likelihood of future events, and the inability to eliminate fraud and misconduct completely. As a result, therecan be no assurance that the Company’s disclosure controls and procedures and internal control over financial reporting willdetect all errors or fraud. However, the Company’s control systems have been designed to provide reasonable assurance ofachieving their objectives, and the Company’s Principal Executive Officer and Principal Financial Officer have concludedthat the Company’s disclosure controls and procedures and internal control over financial reporting are effective at thereasonable assurance level.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 25; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 9B.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Other Information.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PART III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 10.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Directors, Executive Officersand Corporate Governance.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">        The information requiredby this item is incorporated by reference to the section entitled “Directors and Executive Officers” to be containedin the Company’s 2021 Proxy Statement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">        <b>         <u>          Code of Ethics         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has adopteda Code of Business Conduct and Ethics that applies to all officers, directors, and employees serving in any capacity to the Company,including the Chief Executive Officer and/or President, Chief Financial Officer, and Principal Accounting Officer. A copy of theCompany's Code of Business Conduct and Ethics is available on the Company's website at http://www.u-g.com/corporate.The Company intends to satisfy the disclosure requirement under Item 5.05 of Form 8-K relating to amendments to or waivers fromany provision of its Code of Business Conduct and Ethics applicable to the Chief Executive Officer, Chief Financial Officer, andPrincipal Accounting Officer by posting this information on the Company's website.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">        <b>         <u>          Audit Committee         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has anAudit Committee (“Committee”) that is currently composed of three of the Company’s independent directors, aswell as an additional outside director that has expertise in both accounting and financial reporting, who acts as an advisor tothe Committee. The members of the Committee are elected annually by the Board of Directors. The Committee was established for thepurpose of assisting the Board of Directors in fulfilling its oversight responsibilities, including (a) overseeing the Company’saccounting and financial reporting processes, including preparation of financial statements and audits; (b) assuring the Company’scompliance with all legal, regulatory, and ethical responsibilities; (c) evaluating the qualifications and independence of theCompany’s independent accountants; and (d) assessing the effectiveness of the Company’s internal controls and riskmanagement procedures. The Committee currently meets five times a year, and is governed by a charter that was adopted in 2006 andupdated in 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 11.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Executive Compensation.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information requiredby this item is incorporated herein by reference to the section entitled "Compensation of Directors and Executive Officers"in the Company's 2021 Proxy Statement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 26; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 12.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Security Ownership of Certain                                                                                                                                                    Beneficial Owners and Management and Related Stockholder Matters.           </b>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information requiredby this item is incorporated by reference to the section entitled "Voting Securities and Principal Stockholders" in theCompany's 2021 Proxy Statement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 13.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Certain Relationshipsand Related Transactions, and Director Independence.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -63pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The information requiredby this item is incorporated by reference to the section entitled “Directors and Executive Officers" in the Company's2021 Proxy Statement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 14.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Principal AccountingFees and Services.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -63pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Audit Fees         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The aggregate feesthat have been billed by Baker Tilly US, LLP (“Baker Tilly“), the Company’s principal accountants since March25, 2019, for the quarterly reviews of the Company’s financial statements for the first, second and third quarters of 2019and the audit of the Company’s financial statements for the 2019 fiscal year were $89,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The aggregate feesthat have been, or are expected to be, billed by Baker Tilly for the quarterly reviews of the Company’s financial statementsfor the first, second and third quarters of 2020 and the audit of the Company’s financial statements for the 2020 fiscalyear are $89,500.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020, theCompany paid Raich Ende Malter &amp; Co (“Raich”) $5,000 in connection with the audit of the Company’sfinancial statements for the 2019 fiscal year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Audit-RelatedFees         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020, therewere no fees paid to Baker Tilly in connection with the Company's compliance with Section 404 of the Sarbanes-Oxley Act of 2002.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        No other feeswere billed by Baker Tilly for the last two fiscal years that were reasonably related to the performance of the audit or reviewof the Company's financial statements and not reported under "Audit Fees" above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Tax Fees         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There were no feesbilled by Baker Tilly during the last two fiscal years for professional services rendered for tax compliance, tax advice, or taxplanning. Accordingly, none of such services were approved pursuant to pre-approval procedures or permitted waivers thereof.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          All Other Fees         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There were no othernon-audit-related fees billed to the Company by Baker Tilly in 2020 or 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 27; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <b>         <u>          Pre-ApprovalPolicies and Procedures         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Engagement of accountingservices by the Company is not made pursuant to any pre-approval policies and procedures. Rather, the Company believes that itsaccounting firm is independent because all of its engagements by the Company are approved by the Company's Audit Committee priorto any such engagement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Audit Committeemeets periodically to review and approve the scope of the services to be provided to the Company by its Independent RegisteredPublic Accounting Firm, as well as to review and discuss any issues that may arise during an engagement. The Committee is responsiblefor the prior approval of every engagement of the Company's Independent Registered Public Accounting Firm to perform audit andpermissible non-audit services for the Company, such as quarterly financial reviews, tax matters, and consultation on new accountingand disclosure standards.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Before the auditorsare engaged to provide those services, the President and the Controller will make a recommendation to the Committee regarding eachof the services to be performed, including the fees to be charged for such services. At the request of the Committee, the IndependentRegistered Public Accounting Firm and/or management shall periodically report to the Committee regarding the extent of servicesbeing provided by the Independent Registered Public Accounting Firm, and the fees for the services performed to date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 15.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Exhibits, Financial Statement Schedules.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Documents filed as part of this report.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 3%">          </td>          <td style="width: 5%">          </td>          <td style="width: 92%">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (i)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial Statements - see Item 8. Financial Statements and Supplementary Data.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (ii)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial Statement Schedules – None. (Financial statement schedules have been omitted either because they are not applicable, not required, or the information required to be set forth therein is included in the financial statements or notes thereto.)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (iii)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Report of Independent Registered Public Accounting Firm.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (iv)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Notes to Financial Statements.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (b)           </font>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exhibits           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The exhibits listed on the accompanying Exhibit Index are filed as part of this Annual Report.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-indent: -63.35pt">        <b>        </b>       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-indent: -63.35pt">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; width: 63pt">           <b>            Item 16.           </b>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <b>            Form 10-K Summary.           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 28; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <u>         SIGNATURES        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Pursuantto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report tobe signed on its behalf by the undersigned, thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <br/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td>          </td>          <td>          </td>          <td colspan="2">           UNITED-GUARDIAN, INC.          </td>         </tr>         <tr style="vertical-align: top; text-align: left">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; text-align: left">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="width: 34%">          </td>          <td style="width: 2%">           By:          </td>          <td style="width: 31%">           <u>            /s/ Ken Globus           </u>          </td>         </tr>         <tr style="vertical-align: top; text-align: left">          <td>          </td>          <td>          </td>          <td>          </td>          <td>           Ken Globus          </td>         </tr>         <tr style="vertical-align: top; text-align: left">          <td>           Date: March 18, 2021          </td>          <td>          </td>          <td>          </td>          <td>           President and Director          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to the requirements of the SecuritiesExchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacitiesand on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Signature           </font>          </td>          <td>          </td>          <td style="border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="text-align: center">            Title           </p>          </td>          <td>          </td>          <td style="border-bottom: Black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Date           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: right">          </td>         </tr>         <tr>          <td style="vertical-align: top; width: 4%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            By:            <u>            </u>           </p>          </td>          <td style="vertical-align: top; width: 16%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <u>             /s/ KenGlobus            </u>           </p>          </td>          <td style="width: 1%">          </td>          <td style="text-align: left; vertical-align: top; width: 62%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President (Principal Executive Officer); General Counsel; Chairman of the Board of Directors           </font>          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: bottom; width: 16%">          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           Ken Globus          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: bottom">           <font style="font: 10pt Times New Roman, Times, Serif">            March 18, 2021           </font>          </td>         </tr>         <tr>          <td colspan="2" style="vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td colspan="2" style="vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            By:            <u>            </u>           </p>          </td>          <td style="vertical-align: top">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <u>             /s/ Andrea J. Young            </u>           </p>          </td>          <td>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer (Controller, Principal Financial Officer, and Principal Accounting Officer); Treasurer; Secretary           </font>          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           Andrea J. Young          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>          <td>          </td>          <td style="vertical-align: bottom">           <font style="font: 10pt Times New Roman, Times, Serif">            March 18, 2021           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td colspan="2" style="vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>          <td>          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <u>             /s/  Lawrence F. Maietta            </u>           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director; Advisor to the Audit Committee           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 18, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lawrence F. Maietta           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <u>             /s/ Arthur M. Dresner            </u>           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director; Chairman of the Audit Committee           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 18, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Arthur M. Dresner           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <u>             /s/ Andrew A. Boccone            </u>           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director; Audit Committee member           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 18, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Andrew A. Boccone           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <u>             /s/ S. Ari Papoulias            </u>           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director; Audit Committee member           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 18, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            S. Ari Papoulias           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <u>         EXHIBIT INDEX        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Exhibit # Description        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 4%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2           </font>          </td>          <td style="width: 2%; text-align: right">          </td>          <td style="width: 5%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            P           </font>          </td>          <td style="width: 89%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate    of Merger of United-Guardian, Inc. (New York) with and into United-Guardian, Inc.  (Delaware) as filed with the    Secretary of State of the State of Delaware on September 10, 1987. Incorporated by reference to Exhibit 3(b) of the Registrant's    Annual Report on Form 10-K for the fiscal year ended February 29, 1988 (the "1988 10-K").           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            P           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           </p>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Incorporation    of the Company as filed April 22, 1987. Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form    8-K, dated September 21, 1987 (the "1987 8-K").           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (b)           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            P           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By-laws    of the Company. Incorporated by reference to Exhibit 4.2 to the 1987 8-K.           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td rowspan="2" style="vertical-align: top">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            P           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>          <td rowspan="2" style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Specimen    Certificate for shares of Common Stock of the Company. Incorporated by reference to Exhibit 4(a) to the 1988 10-K.           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            P           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Qualified Retirement Income Plan for Employees    of the Company, as restated April 1, 1976.  Incorporated by reference to Exhibit 11(c) of the Registrant's Registration    Statement on Form S-1 (Registration No. 2-63114) declared effective February 9, 1979.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (b)           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000010129501000001/0000101295-01-000001-0002.txt">             Exclusive Distributor Agreement between the Company and ISP Technologies Inc., dated July 5, 2000. Incorporated by reference to Exhibit 10(d) of the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2000.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (c)           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000010129503000001/fy2002_10-ksb.txt">             Letter Amendment between the Company and ISP Technologies Inc. dated December 16, 2002 amending the Exclusive Distributor Agreement between the Registrant and ISP Technologies Inc. dated July 5, 2000. Incorporated by reference to Exhibit 10(d) to the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2002.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (d)           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000010129506000003/exhibit10d.txt">             Letter Amendment between the Company and ISP Technologies Inc. dated December 20, 2005 amending the Exclusive Distributor Agreement between the Registrant and ISP Technologies Inc. dated July 5, 2000 and amended on December 31, 2002. Incorporated by reference to Exhibit 10(d) of the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (e)           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000117184310001636/exh_101.htm">             Letter Amendment between the Company and ISP Technologies Inc. dated May 5, 2010 amending the Exclusive Distributor Agreement between the Company and ISP Technologies Inc. dated July 5, 2000 and amended on December 16, 2002 and December 20, 2005. Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (f)           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000117184313004695/exh_101.htm">             Manufacturing and Supply Agreement between the Company and Smiths Medical ASD, Inc. signed November 12, 2013 and effective as of November 1, 2013. Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K dated and filed November 18, 2013.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/101295/000117184320002021/exh_14.htm">             Code    of Ethics and amendments thereto. Incorporated by reference to Exhibit 14 of the Registrant's Annual Report on Form 10-K for    the fiscal year ended December 31, 2019.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            21           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Subsidiaries    of the Company: None           </font>          </td>         </tr>         <tr>          <td style="text-align: right">          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; text-align: right; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.1           </font>          </td>          <td style="vertical-align: top; width: 2%">          </td>          <td style="vertical-align: top; padding-left: 9.6pt; width: 5%">          </td>          <td style="text-align: justify; width: 89%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="exh_311.htm">             Certification of Ken Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            </a>           </font>          </td>         </tr>         <tr>          <td style="text-align: right">          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.2           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; padding-left: 9.6pt">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="exh_312.htm">             Certificationof Andrea J. Young, Principal Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; padding-left: 9.6pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; padding-left: 9.6pt">          </td>          <td>           <a href="exh_32.htm">            Certifications of Ken Globus, President and Principal Executive Officer of the Company, and Andrea J. Young, Principal Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.           </a>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        P: Indicates a paper filing       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 31; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        INDEX TO FINANCIAL STATEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (For the years ended       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        December 31, 2020 and 2019)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="2" style="text-align: center">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            <u>             Page            </u>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="text-align: center">          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">           <a href="#ReportofIndependentReporting">            <font style="font-family: Times New Roman, Times, Serif">             Reports of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="text-align: right">           <a href="#ReportofIndependentReporting">            <font style="font-family: Times New Roman, Times, Serif">             F-2            </font>           </a>          </td>         </tr>         <tr>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif">            Financial Statements           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="padding-left: 0.25in">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="width: 2%">          </td>          <td style="width: 84%">           <a href="#StatementsOfIncome">            Statements of Income           </a>          </td>          <td style="text-align: right; width: 14%">           <a href="#StatementsOfIncome">            <font style="font-family: Times New Roman, Times, Serif">             F-3            </font>           </a>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <a href="#BalanceSheets">            <font style="font-family: Times New Roman, Times, Serif">             Balance Sheets            </font>           </a>          </td>          <td style="text-align: right">           <a href="#BalanceSheets">            <font style="font-family: Times New Roman, Times, Serif">             F-4 &amp;    F-5            </font>           </a>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <a href="#StockholdersEquity">            <font style="font-family: Times New Roman, Times, Serif">             Statements of Stockholders' Equity            </font>           </a>          </td>          <td style="text-align: right">           <a href="#StockholdersEquity">            <font style="font-family: Times New Roman, Times, Serif">             F-6            </font>           </a>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <a href="#StatementsOfCashFlows">            <font style="font-family: Times New Roman, Times, Serif">             Statements of Cash Flows            </font>           </a>          </td>          <td style="text-align: right">           <a href="#StatementsOfCashFlows">            <font style="font-family: Times New Roman, Times, Serif">             F-7            </font>           </a>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2">          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <a href="#NotesToFinancialStatements">            <font style="font-family: Times New Roman, Times, Serif">             Notes to Financial Statements            </font>           </a>          </td>          <td style="text-align: right">           <a href="#NotesToFinancialStatements">            <font style="font-family: Times New Roman, Times, Serif">             F-8 - F-22            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 32; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="ReportofIndependentReporting">        </a>        <b>         REPORT OF INDEPENDENT REGISTERED        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         PUBLIC ACCOUNTING FIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To the shareholders and the board of directors of United-Guardian,Inc.:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Opinion on the Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have audited the accompanying balance sheets of United-Guardian,Inc. (the "Company") as of December 31, 2020 and 2019, the related statements of income, stockholders' equity, and cashflows, for the years then ended, and the related notes (collectively referred to as the "financial statements"). In ouropinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accountingprinciples generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These financial statements are the responsibility of the Company'smanagement. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a publicaccounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are requiredto be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules andregulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We conducted our audits in accordance with the standards ofthe PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financialstatements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engagedto perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understandingof internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company'sinternal control over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audits included performing procedures to assess the risksof material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond tothose risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financialstatements. Our audits also included evaluating the accounting principles used and significant estimates made by management, aswell as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basisfor our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Critical Audit Matters        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Critical audit matters are matters arising from the currentperiod audit of the financial statements that were communicated or required to be communicated to the audit committee and that:(1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,subjective, or complex judgments. We determined that there are no critical audit matters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: lightgrey">         [Signature]        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Baker Tilly US, LLP (formerly known as Baker Tilly Virchow Krause,LLP)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 33; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="StatementsOfIncome">         </a>         STATEMENTS OF INCOME         <br/>         <br/>        </b>       </p>       <div data-td-statement-type="income" data-td-taggable-table="">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="7" style="text-align: center">            Years ended December 31,           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2020            </font>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2019            </font>           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="3" style="text-align: right">           </td>           <td>           </td>           <td colspan="3" style="text-align: right">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="width: 74%; text-align: left; padding-bottom: 1pt">            Net sales           </td>           <td style="width: 1%; padding-bottom: 1pt">           </td>           <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">            $           </td>           <td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">            10,986,081           </td>           <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="width: 1%; padding-bottom: 1pt">           </td>           <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">            $           </td>           <td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">            13,599,084           </td>           <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Costs and expenses:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt">            Cost of sales           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,872,335           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            5,657,353           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt">            Operating expenses           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            2,026,368           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            2,148,375           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt">            Research and development           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            451,208           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            397,391           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Total    costs and expenses             </b>            </font>           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            7,349,911           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            8,203,119           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Income from operations             </b>            </font>           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            3,636,170           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            5,395,965           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Other income:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; text-align: left">            Investment income           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            226,245           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            203,329           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Net gain on marketable securities           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            298,585           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            431,076           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Total other income           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            524,830           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            634,405           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; font-weight: bold; text-align: left">            Income before provision for income taxes           </td>           <td style="font-weight: bold">           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; text-align: right">            4,161,000           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold">           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; text-align: right">            6,030,370           </td>           <td style="font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left; padding-bottom: 1pt">            Provision for income taxes           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            856,022           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            1,268,659           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">            Net income           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            3,304,978           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            4,761,711           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 2.5pt">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left; padding-bottom: 2.5pt">            Earnings per common share (basic and diluted)           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            0.72           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            1.04           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 2.5pt">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>            Weighted average shares (basic and diluted)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,594,319           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,594,319           </td>           <td style="text-align: left">           </td>          </tr>         </tbody>        </table>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        See Notes to FinancialStatements       </p>       <!-- Field: Page; Sequence: 34; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-size: 10pt">         <a name="BalanceSheets">         </a>         <b>          BALANCESHEETS         </b>        </font>        <br/>        <br/>        <u>         ASSETS        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <div data-td-statement-type="balance-sheet" data-td-taggable-table="">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: bottom">           <td colspan="9">           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="7" style="text-align: center">            December 31,           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            2020           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            2019           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Current assets:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; width: 74%; text-align: left">            Cash and cash equivalents           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            591,444           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            1,048,311           </td>           <td style="width: 1%; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left">            Marketable securities           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            7,591,381           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            6,867,516           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; text-align: left">            Accounts receivable, net of allowance for doubtful accounts of $14,017 in 2020 and $21,178 in 2019           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            1,387,698           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            2,098,411           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left">            Inventories (net)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            1,415,773           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            1,217,277           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; text-align: left">            Prepaid expenses and other current assets           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            161,208           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            170,466           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt;  text-align: left; padding-bottom: 1pt">            Prepaid income taxes           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            99,107           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            165,300           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Total current assets           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            11,246,611           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            11,567,281           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Property, plant, and equipment:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt">            Land           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            69,000           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            69,000           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left">            Factory equipment and fixtures           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,516,335           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,482,236           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Building and improvements           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            2,848,585           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            2,839,289           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; font-weight: bold; text-align: left">            Total property, plant and equipment           </td>           <td style="font-weight: bold">           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; text-align: right">            7,433,920           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold">           </td>           <td style="font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; text-align: right">            7,390,525           </td>           <td style="font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Less accumulated depreciation           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            6,760,255           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            6,609,818           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; font-weight: bold; text-align: left">            Total property, plant, and equipment, net           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            673,665           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            780,707           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left; padding-bottom: 1pt">            Other assets (net)           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            ---           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            14,824           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">            TOTAL ASSETS           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            11,920,276           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            12,362,812           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>          </tr>         </tbody>        </table>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See Notes to Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 35; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-size: 10pt">         <b>          BALANCESHEETS         </b>        </font>        <br/>        <br/>        <u>         LIABILITIES AND STOCKHOLDERS' EQUITY        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <div data-td-statement-type="balance-sheet" data-td-taggable-table="">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="7" style="text-align: center">            December 31,           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2020            </font>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2019            </font>           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Current liabilities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; width: 74%; text-align: left">            Accounts payable           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            31,800           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            71,385           </td>           <td style="width: 1%; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left">            Accrued expenses           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            1,363,457           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            1,129,126           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">            Dividends payable           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            19,028           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            142,548           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Total current liabilities           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            1,414,285           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            1,343,059           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left; padding-bottom: 1pt">            Deferred income taxes (net)           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            151,684           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            386,855           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Commitments and contingencies           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Stockholders’ equity:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">            Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2020 and 2019, respectively           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            459,432           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            459,432           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Retained earnings           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            9,894,875           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            10,173,466           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Total stockholders’ equity           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            10,354,307           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            10,632,898           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 40pt; text-align: left; padding-bottom: 2.5pt">            <p style="text-align: left">             <b>              TOTAL LIABILITIES AND STOCKHOLDERS’                                         EQUITY             </b>            </p>           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            11,920,276           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">            12,362,812           </td>           <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">           </td>          </tr>         </tbody>        </table>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <br/>        See Notes to Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 36; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="StockholdersEquity">         </a>         STATEMENTS OF STOCKHOLDERS' EQUITY         <br/>         <br/>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Years ended December 31, 2020 and 2019       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <div data-td-statement-type="stockholders-equity" data-td-taggable-table="">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: bottom">           <td style="text-align: center">           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">            Common stock           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3">           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3" style="text-align: center">           </td>          </tr>          <tr style="vertical-align: bottom">           <td style="text-align: center">           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">            Shares           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">            Amount           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">            Retained            <br/>            earnings           </td>           <td style="padding-bottom: 1pt">           </td>           <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">            Total           </td>          </tr>          <tr style="vertical-align: bottom">           <td style="text-align: center">           </td>           <td>           </td>           <td colspan="3" style="text-align: center">           </td>           <td>           </td>           <td colspan="3" style="text-align: center">           </td>           <td>           </td>           <td colspan="3" style="text-align: center">           </td>           <td>           </td>           <td colspan="3" style="text-align: center">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="width: 48%; font-weight: bold">            Balance, January 1, 2019           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 10%; text-align: right">            4,594,319           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            459,432           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            10,465,506           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            10,924,938           </td>           <td style="width: 1%; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Net income           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,761,711           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,761,711           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Dividends declared, not paid ($1.10 per share)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (3,829           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (3,829           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Dividends declared and paid ($1.10 per share)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (5,049,922           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (5,049,922           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-bottom: 1pt">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="font-weight: bold">            Balance, December 31, 2019           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,594,319           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">            $           </td>           <td style="text-align: right">            459,432           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">            $           </td>           <td style="text-align: right">            10,173,466           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">            $           </td>           <td style="text-align: right">            10,632,898           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Net income           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            3,304,978           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            3,304,978           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Dividends declared, not paid ($0.78 per share)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (1,138           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (1,138           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Dividends declared and paid ($0.78 per share)           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (3,582,431           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (3,582,431           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 1pt">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-weight: bold; padding-bottom: 2.5pt">            Balance, December 31, 2020           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            4,594,319           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            459,432           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            9,894,875           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            10,354,307           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>          </tr>         </tbody>        </table>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See Notes to Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 37; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="StatementsOfCashFlows">         </a>         <br/>         STATEMENTS OF CASH FLOWS         <br/>         <br/>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <div data-td-statement-type="cash-flows" data-td-taggable-table="">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="7" style="text-align: center">            Years ended December 31,           </td>          </tr>          <tr style="vertical-align: bottom">           <td>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2020            </font>           </td>           <td>           </td>           <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2019            </font>           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left">            Cash flows from operating activities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; width: 74%; text-align: left">            Net income           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            3,304,978           </td>           <td style="width: 1%; text-align: left">           </td>           <td style="width: 1%">           </td>           <td style="width: 1%; text-align: left">            $           </td>           <td style="width: 10%; text-align: right">            4,761,711           </td>           <td style="width: 1%; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left">            Adjustments to reconcile net income to net cash provided by operating activities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; text-align: left">            Depreciation and amortization           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            165,261           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            175,810           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left">            Net gain on marketable securities           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (298,585           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (431,076           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; text-align: left">            Allowance for doubtful accounts           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (7,161           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            4,283           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left">            Reserve for inventories           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            ---           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            15,000           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; text-align: left">            Deferred income taxes           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (235,171           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            133,272           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left">            Decrease (increase) in operating assets:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; text-align: left">            Accounts receivable           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            717,874           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (430,127           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 30pt">            Inventories           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (198,496           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            249,874           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; text-align: left">            Prepaid expenses and other current assets           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            9,258           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (11,102           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 30pt; text-align: left">            Prepaid income taxes           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            66,193           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            35,387           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 20pt; text-align: left">            (Decrease) increase in operating liabilities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 30pt; text-align: left">            Accounts payable           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (39,585           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (115,412           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 30pt; text-align: left">            Accrued expenses           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            234,331           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            88,491           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">            Dividends payable           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            (124,657           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">            )           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            ---           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Net cash provided by operating activities           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            3,594,240           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            4,476,111           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Cash flows from investing activities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left">            Acquisitions of property, plant and equipment           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (43,395           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (113,769           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 10pt; text-align: left">            Purchases of marketable securities           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (6,796,409           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (14,779,161           </td>           <td style="text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Proceeds from sales of marketable securities           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            6,371,128           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            15,964,917           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Net cash (used in) provided by investing activities           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            (468,676           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">            )           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            1,071,987           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Cash flows from financing activities:           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">            Dividends paid           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            (3,582,431           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">            )           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            (5,049,922           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 1pt">            Net cash used in financing activities           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            (3,582,431           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">            )           </td>           <td style="font-weight: bold; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">            (5,049,922           </td>           <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">            )           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left">            Net (decrease) increase in cash and cash equivalents           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            (456,867           </td>           <td style="text-align: left">            )           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">            498,176           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td>           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td>           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="text-align: left; padding-bottom: 1pt">            Cash and cash equivalents, beginning of year           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            1,048,311           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; text-align: right">            550,135           </td>           <td style="border-bottom: Black 1pt solid; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="text-align: left; padding-bottom: 2.5pt">            Cash and cash equivalents, end of year           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            591,444           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            1,048,311           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 2.5pt">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">            Supplemental disclosure of cash flow information           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 2.5pt">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">            Taxes paid           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            1,025,000           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            1,100,000           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="padding-bottom: 2.5pt">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="text-align: left">           </td>           <td style="text-align: right">           </td>           <td style="text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">            Supplemental disclosure of non-cash dividends on unexchanged shares           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            1,138           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>           <td style="padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; text-align: right">            3,829           </td>           <td style="border-bottom: Black 2.5pt double; text-align: left">           </td>          </tr>         </tbody>        </table>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See Notes to Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 38; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="NotesToFinancialStatements">        </a>        <b>         NOTES TO FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <br/>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">         <b>          NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Nature of Business          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         United-Guardian, Inc.(the "Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures and marketscosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It also conducts research and productdevelopment, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and developmentdepartment also modifies, refines, and expands the uses for existing products, with the goal of further developing the market forthe Company's products. Two major product lines, Lubrajel         <sup>          ®         </sup>         and Renacidin         <sup>          ®         </sup>         Irrigation Solution (“Renacidin”)together accounted for approximately 92% and 93% of the Company’s sales for the years ended December 31, 2020 and December31, 2019, respectively. Lubrajel accounted for approximately 57% and 67% of the Company’s sales for the years ended December31, 2020 and December 31, 2019, respectively, and Renacidin accounted for approximately 36% and 26% of the Company’s salesfor the years ended December 31, 2020 and December 31, 2019, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Impact of the Coronavirus Pandemic          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         In March 2020, thespread of the coronavirus (COVID-19) began to cause disruptions among businesses and markets worldwide. On March 20, 2020, theGovernor of New York issued an executive order which closed non-essential businesses. The Company, as a manufacturer of pharmaceuticaland medical products, was considered an essential business, and continued to operate throughout the pandemic. When the spread ofthe coronavirus was at its worst in New York the Company modified its staffing schedule in order to decrease employee density asmuch as possible, with employees working 7 days a week on altered hours, and later on an every-other-week work schedule with limitedhours. Despite the reduced schedule the Company was able to maintain adequate production and shipping schedules, and was able tofill all orders on a timely basis. As things improved, the Company gradually increased its working hours and employee density untilit resumed its regular working schedule in June 2020. Throughout the pandemic the Company was able to maintain its full payroll,all employees received their full pay, and no employees were furloughed or dismissed.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         While the Company’spharmaceutical sales have not been impacted by the coronavirus pandemic, sales of the Company’s cosmetic ingredients andmedical products have been significantly impacted, particularly in the second half of 2020. Sales of the Company’s cosmeticingredients in 2020 decreased by 33% compared with 2019. The decrease was primarily the result of lower sales to Ashland SpecialtyIngredients (“ASI”), the Company’s marketing partner in China, and was caused primarily by factors related tothe coronavirus, including (a) lower consumer demand in China for many of the products in which the Company’s products areused; (b) manufacturing disruptions in China resulting from the impact of the coronavirus on manufacturing facilities; and (c)excess inventory levels due to overstocking on the part of both the Company’s marketing partner for China as well its sub-distributorsin China. The overstocking was due to the uncertainty on the part of the marketing partner about being able to continue to getproduct from the Company during the pandemic.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Since the Company’scosmetic ingredients are marketed in many different countries, it is difficult to project the future impact of the coronaviruspandemic on the Company’s global cosmetic ingredient sales, since the virus continues to impact different countries at differenttimes and to very different extents. The Company is hopeful that as vaccinations increase, the global economic situation will graduallyimprove. However, based on the current situation, as well as future projections by different analysts, the Company anticipatesthat the pandemic will continue to negatively impact sales of the Company’s cosmetic ingredients throughout most or all of2021.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 39; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             8             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company also believesthat the coronavirus impacted sales to two of the Company’s four medical product customers whose orders decreased in 2020,and may have been a factor in the loss of a third (although the Company has not yet been able to confirm that as the reason forthat lost business). Overall sales of the Company’s medical products decreased by 31% compared with the corresponding periodsin 2019.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         With the continuinguncertainty as to what the duration and future impact of the pandemic will be, the Company is unable to provide an accurate estimateor projection as to what the continuing impact of the coronavirus will be on the Company’s operations or its financial resultsin the future. However, as of the date of this report, the Company does not anticipate that the coronavirus pandemic will affectthe ability of the Company to obtain raw materials and maintain production. The Company has protection from large price fluctuationson its most important raw material, and has multiple sources for many of its other raw materials. Even with the impact of the coronaviruspandemic it has been able to maintain sufficient inventory and production levels to enable it to fulfill sales orders on a timelybasis. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Use of Estimates          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         In preparing financialstatements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”),management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosureof contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period.Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventoryobsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocationof overhead.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Accounts Receivable and Reserves          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The carrying amountof accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts thatwill not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts and sales returns. Inaddition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, includinghistorical data, experience, customer types and credit worthiness, and economic trends. At December 31, 2020 and 2019, the allowancefor doubtful accounts receivable amounted to $14,017 and $21,178, respectively.  From time to time, the Company adjusts itsassumptions for anticipated changes in any of these or other factors expected to affect collectability.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Revenue Recognition          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company recordsrevenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognizedwhen a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be receivedin exchange for those goods or services. The Company’s principal source of revenue is product sales.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 40; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             9             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company’ssales, as reported, are subject to a variety of deductions, which are estimated and recorded in the same period that the revenuesare recognized. Such variable consideration, primarily related to the sale of the Company’s pharmaceutical products, includeschargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with participationin Medicare and Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimatesof the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductionson sales for a reporting period.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         During 2020 and 2019,the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceuticalproduct. These programs include the Medicaid Drug Rebate Program (MDRP), Section 340B Drug Pricing Program (340B), Veterans AffairsFederal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs required the Companyto either sell its product at a discounted price, or, in the case of Medicaid, to pay a significant rebate to the various stateswhere Renacidin is provided to Medicaid patients. The Company’s sales, as reported, are net of these rebates, some of whichare estimated and are recorded in the same period that the revenue is recognized.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         As a result ofthe overly burdensome nature of the Medicaid rebates, the Company concluded in October 2020 that it was no longer profitablefor the Company to continue participating in the Medicaid or the 340B programs. As a result, on October 30, 2020, the Companyinformed the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and Services Administration (HRSA)of its intention to terminate its Medicaid Drug Rebate Agreement and its 340B Drug Pricing Agreement, effective as ofDecember 31, 2020. The Company will, however, continue to participate in the other government discount and rebate programs,specifically the Veterans Affairs FSS Program and the Medicare Part D Coverage Gap Program (CGDP).        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         As long as a validpurchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenuefrom sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied.The Company’s products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the riskof loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceuticalmedical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow thereturn of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless(a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than oneyear after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Companyestimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company does notmake sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingentupon the customer being able to sell the goods to a third party.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Any allowances forreturns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined basedon historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimatedallowances and actual activity.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The timing betweenrecognition of revenue for product sales and the receipt of payment is not significant. Due to the Covid-19 pandemic the Companyexperienced minor delays in receiving payments from certain customers that were impacted by the pandemic, but the negative impactof those delayed payments was not significant. The Company’s standard credit terms, which vary depending on the customer,range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstandingreceivables and provides allowances for any receivables for which collection has become doubtful. As of December 31, 2020 and December31, 2019, the allowance for doubtful accounts receivable was $14,017 and $21,178, respectively. Prompt-pay discounts are offeredto some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when theyare taken.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 41; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             10             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company has distributionagreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-relatedfees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Disaggregated net salesby product class is as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 0pt">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: center">             2020            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: center">             2019            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 66%; text-align: left">             Cosmetic ingredients            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 14%; text-align: right">             4,274,586            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 14%; text-align: right">             6,377,323            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td>             Pharmaceuticals            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             4,519,052            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             4,091,817            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Medical products            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,052,961            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,968,806            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Industrial and other            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             139,482            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             161,138            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">             Total Net Sales            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             10,986,081            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             13,599,084            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 0pt">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company’scosmetic ingredients are currently marketed worldwide by five marketing partners, of which United States (“U.S.”)-basedASI purchases the largest volume. During most of 2019 the Company also had a separate marketing partner for Korea, but at the endof 2019 that territory was transferred to ASI. For the years ended December 31, 2020 and 2019, approximately 20% and 18%, respectively,of the Company’s sales were to (a) its foreign-based marketing partners (which does not include ASI), which marketed anddistributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’smedical products.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Disaggregated salesby geographic region are as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2019             </font>            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 66%; text-align: left">             United States*            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 14%; text-align: right">             8,796,221            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 14%; text-align: right">             11,118,629            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Other countries            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             2,189,860            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             2,480,455            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">             Net Sales            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             10,986,081            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             13,599,084            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         * Although a significantpercentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. salesfor financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentageof those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Companyby ASI, 68% of ASI’s sales in 2020 were to customers in foreign countries, compared to 75% in 2019. ASI’s largest foreignmarket in both 2020 and 2019 was China, which accounted for approximately 33% of ASI’s sales in 2020 and 49% of sales in2019.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 42; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             11             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Cash and Cash Equivalents          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         For financial statementpurposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months orless at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions andbelieves that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accountsare currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December31, 2020, approximately $653,000 exceeded the FDIC limit.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Dividends          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         On May 20, 2020, theCompany’s Board of Directors declared a semi-annual cash dividend of $0.42 per share, which was paid on June 17, 2020 toall stockholders of record as of June 3, 2020. On November 18, 2020, the Company’s Board of Directors declared a semi-annualcash dividend of $0.36 per share which was paid on December 8, 2020, to all stockholders of record as of December 1, 2020. In 2020,the Company declared a total of $3,583,569 in dividends, of which $3,582,431 was paid. The balance of $1,138 is payable to stockholderswhose old Guardian shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. See Note H forfurther discussion.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         During the third quarterof 2020, the Company paid approximately $124,041 to its transfer agent, which represented accrued dividends on unconverted Guardianshares. This payment was made to facilitate the conversion of those shares to United-Guardian, Inc. shares, and the subsequentescheatment of those shares to the appropriate state jurisdictions. The Company is continuing to accrue dividends on the remainingunconverted shares that are currently pending escheatment.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         On May 15, 2019, theCompany’s Board of Directors declared a semi-annual cash dividend of $0.55 per share, which was paid on June 14, 2019 toall stockholders of record as of May 31, 2019. On November 20, 2019, the Company’s Board of Directors declared a semi-annualcash dividend of $0.55 per share which was paid on December 10, 2019, to all stockholders of record as of December 3, 2019. In2019, the Company declared a total of $5,053,751 in dividends, of which $5,049,922 was paid. The balance of $3,829 was payableto stockholders whose Guardian shares have not been exchanged to United-Guardian, Inc. shares and are pending escheatment. SeeNote H for further discussion.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Marketable Securities          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company’smarketable securities include investments in equity and fixed income mutual funds and U.S. Government securities. The Company’smarketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in netincome. U.S Treasury Bills are considered debt securities and realized gains or losses, if any, are reported in other comprehensiveincome. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investmentsperiodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fairvalue had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investmentfor a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment chargeto the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the declinein value is determined to be other-than-temporary. During 2020 and 2019, the Company did not record an impairment charge regardingits investment in marketable securities because management believes, based on its evaluation of the circumstances, that the declinein fair value below the cost of certain of the Company’s marketable securities is temporary.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 43; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             12             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Inventories          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Inventories are valuedat the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determinedby the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Property, Plant and Equipment          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Property, plant andequipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routinemaintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciationcharged as a result of using accelerated methods was not materially different than that which would result from using the straight-linemethod for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materialsand in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Estimated useful livesare as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td style="width: 70%">             Factory equipment and fixtures  (years)            </td>            <td style="width: 1%">            </td>            <td style="width: 1%">            </td>            <td style="text-align: center; width: 9%">             5            </td>            <td style="text-align: center; width: 9%">             -            </td>            <td style="text-align: center; width: 9%">             7            </td>            <td style="width: 1%">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Building (years)            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: center">            </td>            <td style="text-align: center">             40            </td>            <td style="text-align: center">            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Building improvements            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td colspan="3" style="text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              Lesser of useful life or 20 years             </font>            </td>            <td style="text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Impairment of Long-Lived Assets          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Long-lived assets andcertain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carryingamount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carryingamount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired,the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value ofthe assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairmentswere necessary at December 31, 2020 and 2019.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Other Assets (net)          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Other assets at December31, 2020 and 2019 represents an amount expended in connection with the development of the current single-dose form of Renacidin.The Company began amortizing these costs in the first quarter of 2016. At December 31, 2020 and 2019, accumulated amortizationfor such assets amounted to $74,120 and $59,296, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Fair Value of Financial Instruments          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Management of the Companybelieves that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable,and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Concentration of Credit Risk          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Accountsreceivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allowseach of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any creditshould be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past dueon its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a resultof its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’ssales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Companybelieves that its accounts receivable credit risk has been reduced.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 44; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             13             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         For the year endedDecember 31, 2020, four of the Company’s distributors and marketing partners accounted for approximately 72% of the Company’sgross sales during the year and approximately 67% of its outstanding accounts receivable at December 31, 2020. For the year endedDecember 31, 2019, the same four distributors and marketing partners accounted for a total of approximately 70% of the Company’sgross sales during the year and 70% of its outstanding accounts receivable at December 31, 2019.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Vendor Concentration          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Most of the principalraw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supplyfrom numerous sources. However, there are some raw materials used by the Company that are not readily available or require longlead times. The Company did not experience any issues obtaining raw materials from its main suppliers during the COVID-19 pandemic.The Company has six major raw material vendors that collectively accounted for approximately 88% and 84% of the raw material purchasesby the Company in 2020 and 2019, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Income Taxes          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Income taxes are accountedfor under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributableto the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective taxbases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax ratesexpected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferredtax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred taxassets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion orall the deferred tax assets will not be realized.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Uncertain tax positionsare accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurementof a tax position taken or expected to be taken in a tax return. As of December 31, 2020 and 2019, the Company did not have anyunrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interestexpense as incurred. During the years ended December 31, 2020 and 2019, the Company did not record any tax-related interest orpenalties. The Company’s tax returns for 2017 and all subsequent years are subject to examination by the United States InternalRevenue Service and by the State of New York.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         On December 18, 2019,the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “Simplifyingthe Accounting for Income Taxes”, which modifies ASC 740 to simplify the accounting for income taxes. The amendments in ASU2019-12 are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating whether any of themodifications included in this pronouncement will impact its financial statements.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 45; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             14             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Research and Development          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Research and developmentexpenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payrollrelated expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Shipping and Handling Expenses          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Shipping and handlingcosts are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately$81,000 and $76,000 for the years ended December 31, 2020 and 2019, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Advertising Expenses          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         <font style="font-size: 10pt">          Advertisingcosts are expensed as incurred. For the years ended December 31, 2020 and 2019, the Company incurred approximately $27,000 and$28,000, respectively, in advertising expense         </font>         ,         <font style="font-size: 10pt">          which primarily relates to the internet marketingof Renacidin, one of the Company’s pharmaceutical products.         </font>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Earnings Per Share Information          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Basic earnings pershare are computed by dividing net income by the weighted average number of common shares outstanding during the year. Dilutedearnings per share would include the dilutive effect of outstanding stock options, if any.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           New Accounting Standards          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         In January 2019, theCompany adopted ASU 2016-02, “Leases”, which was intended to improve financial reporting for lease transactions. ThisASU requires organizations that lease assets, such as real estate and manufacturing equipment, to recognize both assets and liabilitieson their balance sheet for the rights to use those assets for the lease term and obligations to make the lease payments createdby those leases that have terms of greater than 12 months. The recognition, measurement, and presentation of expenses and cashflows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requiresdisclosures to help investors and other financial statement users better understand the amount and timing of cash flows arisingfrom leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amountsrecorded in the financial statements. The adoption of this standard did not have a material impact on the Company’s financialstatements.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         On December 18, 2019,the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes”, which modifies ASU 740 to simplify theaccounting for income taxes. The amendments in ASU 2019-12 are effective for fiscal years beginning after December 15, 2020. Earlyadoption is permitted. The Company is currently evaluating if any of these modifications will have an impact on its financial statements.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         In June 2016, the FASBissued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financialassets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income.The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date basedon historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginningafter December 15, 2022. The Company is currently evaluating if this pronouncement will have a potential impact on its financialstatements.        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 46; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE B - MARKETABLE SECURITIES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Marketable securitiesinclude investments in fixed income and equity mutual funds and U.S. Government securities with maturities greater than 3 months,which are reported at their fair values.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company’sU.S. Treasury Bills are considered debt securities and unrealized gains and losses, if any, are reported in other comprehensiveincome. The U.S. Treasury Bills are considered held to maturity securities, as they are purchased directly from the U.S. Governmentand are unable to be sold before the maturity date.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The disaggregated netgains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2020 and 2019are as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -27pt">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">          <tbody>           <tr style="vertical-align: bottom">            <td style="text-align: justify">            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td style="text-align: justify">            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             2020            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             2019            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 74%; text-align: justify">             Net gains recognized during the year on marketable securities            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             298,585            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             431,076            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; text-indent: -27pt; padding-left: 27pt">             Less: Net gains recognized during the year on marketable securities sold during the period            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (415,595            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (262,399            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">             Unrealized (losses) gains recognized during the reporting year on marketable securities still held at the reporting date            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             (117,010            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             )            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             168,677            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The fair values ofthe Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amountthat would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants atthe measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that marketparticipants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes thethree-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">         •         <font style="font-family: Times New Roman, Times, Serif">          Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.         </font>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">         •         <font style="font-family: Times New Roman, Times, Serif">          Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputsthat are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financialinstrument.         </font>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">         •         <font style="font-family: Times New Roman, Times, Serif">          Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.         </font>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company’smarketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurringbasis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The followingtables summarize the Company’s investments:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 47; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             16             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         <b>          <u>           December 31,2020          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.3pt 0pt 27pt; text-align: right">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.3pt 0pt 27pt; text-align: right">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.3pt 0pt 0; text-align: justify; text-indent: 1.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>             <b>              <u>               Equity Securities              </u>             </b>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             Cost            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             Fair Value            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             Unrealized Gain            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 61%; text-align: left">             Fixed income mutual funds            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             6,703,107            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             6,907,270            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             204,163            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Equity and other mutual funds            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             584,044            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             684,111            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             100,067            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">             Total equity securities            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             7,287,151            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             7,591,381            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             304,230            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">             Total marketable securities            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             7,287,151            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             7,591,381            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             304,230            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">         <b>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">         <b>          <u>           December 31,2019          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td style="font-weight: bold">             <u>              Debt Securities             </u>            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3">            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3">            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: right">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 61%; text-align: left">             U.S Treasury Bills (maturities of greater than three months up to one year)            </td>            <td style="width: 1%">            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">             $            </td>            <td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">             3,481,625            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">             $            </td>            <td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">             3,481,625            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">             $            </td>            <td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">             ---            </td>            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">             Total debt securities            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             3,481,625            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             3,481,625            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             ---            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td style="font-weight: bold">             <u>              Equity Securities             </u>            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: right">            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: right">            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: right">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 61%; text-align: left">             Fixed income mutual funds            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             1,940,071            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             2,122,157            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             182,086            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Equity and other mutual funds            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             1,024,580            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             1,263,734            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             239,154            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">             Total equity securities            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             2,964,651            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             3,385,891            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             421,240            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">             Total marketable securities            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             6,446,276            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             6,867,516            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             421,240            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Investment income isrecognized when earned and consists principally of interest income from fixed income mutual funds and U.S. Treasury Bills and dividendincome from equity and other mutual funds. Realized gains and losses on sales of investments are determined on a specific identificationbasis.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Proceeds from the saleand redemption of marketable securities amounted to $6,371,128 for the year ended December 31, 2020, which included realized gainsof $415,595. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2019 amounted to $15,964,917,which included realized gains of $262,399.        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">         <b>          NOTE C – INVENTORIES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">         Inventories consist of the following:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2019             </font>            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 70%; text-align: left">             Raw materials            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 12%; text-align: right">             415,415            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 12%; text-align: right">             320,507            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Work in process            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             59,258            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             81,002            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left; padding-bottom: 1pt">             Finished products            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             941,100            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             815,768            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">             Total Inventories            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,415,773            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,217,277            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Inventories are valuedat the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determinedby the first-in, first-out method. Finished product inventories at December 31, 2020 and December 31, 2019 are net of a reserveof $35,000. At December 31, 2020 and 2019, the Company had an allowance of $302,715 and $231,392 respectively, for possible outdatedmaterial returns, which is included in accrued expenses. As of the date of this report, the COVID-19 pandemic has not adverselyaffected the valuation of the Company’s finished products, work in process or raw material inventories.        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 48; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE D – INCOME TAXES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">         The provision for income taxes consistsof the following:         <br/>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td>             Current            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2019             </font>            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; width: 74%">             Federal            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             1,091,148            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             1,135,209            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; padding-bottom: 1pt">             State            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             45            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             178            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">             Total current provision for income taxes            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             1,091,193            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             1,135,387            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">          <tbody>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td>             Deferred            </td>            <td>            </td>            <td colspan="3" style="text-align: right">            </td>            <td>            </td>            <td colspan="3" style="text-align: right">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; width: 74%">             Federal            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             (235,171            </td>            <td style="width: 1%; text-align: left">             )            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             133,272            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; padding-bottom: 1pt">             State            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             ---            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             ---            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">             Total    deferred (benefit from) provision for income taxes            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (235,171            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             133,272            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              <b>               Total    provision for income taxes              </b>             </font>            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             856,022            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,268,659            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The following is areconciliation of the Company’s effective income tax rate to the Federal statutory rate (dollar amounts have been roundedto the nearest thousand):        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td style="text-align: center">            </td>            <td style="text-align: center">            </td>            <td colspan="15" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td style="text-align: center">            </td>            <td style="text-align: center">            </td>            <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">             2020            </td>            <td style="text-align: center">            </td>            <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">             2019            </td>           </tr>           <tr style="vertical-align: bottom">            <td style="text-align: center">            </td>            <td style="text-align: center; padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">             ($)            </td>            <td style="text-align: center; padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              Tax    rate             </font>            </td>            <td style="text-align: center; padding-bottom: 1pt">            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             ($)            </td>            <td style="text-align: center; padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">             Tax rate            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 48%; text-align: left">             Income taxes at statutory federal income tax rate            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             874,000            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             21.0            </td>            <td style="width: 1%; text-align: left">             %            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             1,266,000            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             21.0            </td>            <td style="width: 1%; text-align: left">             %            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Nondeductible expenses            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             ---            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             ---            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             1,000            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             ---            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Research  &amp; development credits            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (10,000            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (0.2            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (8,000            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (0.1            </td>            <td style="text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Non-taxable dividends            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (3,000            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (0.1            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (2,000            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             ---            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left; padding-bottom: 1pt">             Other, net            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (5,000            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (0.1            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             12,000            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             0.2            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">             Provision for income taxes            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             856,000            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             20.6            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             %            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,269,000            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             21.1            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             %            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The tax effects oftemporary differences which comprise the deferred tax assets and liabilities are as follows:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2019             </font>            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Deferred tax assets            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; width: 74%; text-align: left">             Allowance for doubtful accounts            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             2,944            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             4,447            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt">             Inventories            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             7,350            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             7,350            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; text-align: left">             Accounts payable            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             6,678            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             14,991            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">             Accrued expenses            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             284,145            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             235,633            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">             Total deferred tax assets            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             301,117            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             262,421            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td>            </td>            <td>            </td>            <td colspan="3">            </td>            <td>            </td>            <td colspan="3">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td>             Deferred tax liabilities            </td>            <td>            </td>            <td colspan="3">            </td>            <td>            </td>            <td colspan="3">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; width: 74%; text-align: left">             Accounts receivable            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             (294,360            </td>            <td style="width: 1%; text-align: left">             )            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 10%; text-align: right">             (445,113            </td>            <td style="width: 1%; text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; text-align: left">             Prepaid expenses            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (33,829            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (42,319            </td>            <td style="text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left">             Depreciation on property, plant and equipment            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (60,724            </td>            <td style="text-align: left">             )            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             (73,384            </td>            <td style="text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">             Unrealized gain on marketable securities            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (63,888            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (88,460            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">             Total deferred tax liabilities            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (452,801            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (649,276            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              <b>               Net    deferred tax liability              </b>             </font>            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             (151,684            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             )            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             (386,855            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             )            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>         </b>        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 49; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE E - BENEFIT PLANS         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          <u>           Defined Contribution Plan          </u>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company sponsorsa 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution ofthe first 4% of each employee's pay. Employees become fully vested in employer matching contributions after one year of employment.Company 401(k) matching contributions were approximately $83,000 and $88,000 for the years ended December 31, 2020 and 2019, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company also makesdiscretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the401(k) Plan under current IRS regulations. For the years ended December 31, 2020 and 2019, the Company’s Board of Directorsauthorized discretionary contributions in the amount of $130,000 and $145,000, respectively, to be allocated among all eligibleemployees. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% foreach year of employment thereafter until the employee becomes fully vested after six years of employment.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE F - GEOGRAPHIC and OTHER INFORMATION         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Through its GuardianLaboratories division the Company manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialtyindustrial products. It also conducts research and development, primarily related to the development of new and unique cosmeticingredients. The Company’s R&amp;D department not only develops new products but also modifies and refines existing products,with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufacturedby the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many ofthe major multinational personal care products companies.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The Company operatesin one business segment. The Company’s products are separated into four distinct product categories: cosmetic ingredients,pharmaceuticals, medical products, and industrial products. Each product category is marketed differently. The cosmetic ingredientsare marketed through a global network of marketing partners and distributors. These marketing partners purchase product outrightfrom the Company and provide the marketing functions for these products on behalf of the Company. They in turn receive their compensationfor those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have itsproducts marketed without the high cost of maintaining its own in-house marketing staff. The Company has written marketing arrangementswith only one of its global distributors, ASI, and that contract renews every two years unless cancelled for any reason by eitherparty at least 60 days prior to the expiration of the two-year marketing period in effect at that time. The current marketing periodwith ASI ends on December 31, 2021. The Company’s other marketing partners are not under any contractual obligation to marketthe Company’s cosmetic ingredients, and the Company has the ability to cancel those marketing arrangements at any time uponreasonable notice. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective,and the Company does not make any sales on consignment.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <!-- Field: Page; Sequence: 50; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             19             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         No prior regulatoryapproval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products mayor may not need regulatory approvals, depending on the intended claims and uses of those products.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The pharmaceuticalproducts are two urological products that are sold to end users primarily through distribution agreements with the major drug wholesalers.For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitalsand pharmacies. The Company’s marketing efforts for these products are currently centered around the corporate website, aseparate website developed specifically for Renacidin, its most important drug product, and internet marketing using Google ads.Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application(“NDA”), and the current sterile liquid form of Renacidin is being marketed under an NDA that was approved by the FDAin 1990.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The medical productsare not pharmaceutical products. They consist primarily of medical lubricants, which are marketed by the Company directly to manufacturersthat incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguishedfrom the pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatoryapproval prior to marketing these products. Approvals are the responsibility of the company that markets the products in whichthe Company’s products are used, such as medical devices. However, the Company is responsible for manufacturing these productsin accordance with current Good Manufacturing Practices for medical devices.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The industrial productsare also marketed by the Company directly to manufacturers, and generally do not require that the Company obtain regulatory approval.However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         The following tablespresent the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchasesfrom the Company are sold to foreign customers, in table “b” below all sales to Customer A are included in “UnitedStates” sales revenue because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         In addition, thereare four customers for the Company’s medical products that take delivery of their shipments in the U.S. but potentially shipsome of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, salesto those customers are also included in the “United States” revenue number in the table below.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0.25in">           </td>           <td style="width: 0.25in">            (a)           </td>           <td>            <b>             <u>              Net Sales             </u>            </b>            Years ended December 31,           </td>          </tr>         </tbody>        </table>        <p style="margin-top: 0; margin-bottom: 0">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: center">             2020            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td>            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: center">             2019            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 74%; text-align: left">             Cosmetic Ingredients            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             4,283,052            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             6,383,224            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td>             Pharmaceuticals            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             5,959,705            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             5,238,226            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Medical Products            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,054,093            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,971,243            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Industrial and other            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             139,482            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             161,138            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 10pt; text-align: left">             Gross Sales            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             12,436,332            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             14,753,831            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Less: Discounts and allowances            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (1,450,251            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             (1,154,747            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">             )            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              <b>               Net Sales              </b>             </font>            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             10,986,081            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             13,599.084            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="margin-top: 0; margin-bottom: 0">        </p>        <!-- Field: Page; Sequence: 51; Value: 1 -->        <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">         <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="text-align: center; width: 100%">             F-             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->             20             <!-- Field: /Sequence -->            </td>           </tr>          </tbody>         </table>        </div>        <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">         <p style="margin: 0pt">         </p>         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">          <tbody>           <tr style="vertical-align: top; text-align: left">            <td style="width: 100%">             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">              UNITED-GUARDIAN, INC.             </p>            </td>           </tr>          </tbody>         </table>         <p style="margin: 0pt">         </p>        </div>        <!-- Field: /Page -->        <p style="margin-top: 0; margin-bottom: 0">        </p>        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0.25in">           </td>           <td style="width: 0.25in">            <b>             (b)            </b>           </td>           <td>            <b>             <u>              Geographic Information             </u>            </b>           </td>          </tr>         </tbody>        </table>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              Years ended December 31,              <font style="color: white">               .              </font>             </font>            </td>           </tr>           <tr style="vertical-align: bottom">            <td>            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td style="padding-bottom: 1pt">            </td>            <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">             2019            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 74%; text-align: left">             United States            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             8,796,221            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             11,118,629            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left; padding-bottom: 1pt">             Other countries            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             2,189,860            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             2,480,455            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">             Net Sales            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             10,986,081            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             13,599,084            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">         <b>         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">         <b>         </b>        </p>        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0.25in">           </td>           <td style="width: 0.25in">            <b>             (c)            </b>           </td>           <td>            <b>             <u>              Gross Sales to Major Customers             </u>            </b>           </td>          </tr>         </tbody>        </table>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4in">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td style="text-align: justify">            </td>            <td>            </td>            <td colspan="7" style="text-align: center">             Years ended December 31,            </td>           </tr>           <tr style="vertical-align: bottom">            <td style="text-align: justify">            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2020             </font>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">              2019             </font>            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 74%; text-align: justify">             Customer A            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             3,236,113            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             5,349,381            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: justify">             Customer B            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,796,310            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             2,390,911            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: justify">             Customer C            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             1,485,288            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             1,333,891            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: justify">             Customer D            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             1,434,097            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             1,256,640            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: justify; padding-bottom: 1pt">             All other customers            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             3,484,524            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             4,423,008            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">             Total Gross Sales            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             12,436,332            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             14,753,831            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>         </b>        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE G - ACCRUED EXPENSES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         Accrued expenses at December 31, 2020 and2019 consist of:        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <div data-td-taggable-table="">         <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">          <tbody>           <tr style="vertical-align: bottom">            <td>            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             2020            </td>            <td>            </td>            <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">             2019            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="width: 74%">             Bonuses            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             210,000            </td>            <td style="width: 1%; text-align: left">            </td>            <td style="width: 1%">            </td>            <td style="width: 1%; text-align: left">             $            </td>            <td style="width: 10%; text-align: right">             216,000            </td>            <td style="width: 1%; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Distribution fees            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             325,792            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             309,190            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Payroll and related expenses            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             245,521            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             175,433            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Annual report expenses            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             63,432            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             64,324            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Audit fee            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             50,500            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             48,500            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="text-align: left">             Reserve for outdated material            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             302,713            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             231,392            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="text-align: left">             Sales rebates            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             149,346            </td>            <td style="text-align: left">            </td>            <td>            </td>            <td style="text-align: left">            </td>            <td style="text-align: right">             46,100            </td>            <td style="text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: White">            <td style="padding-bottom: 1pt">             Other            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             16,153            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="padding-bottom: 1pt">            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>            <td style="border-bottom: Black 1pt solid; text-align: right">             38,187            </td>            <td style="border-bottom: Black 1pt solid; text-align: left">            </td>           </tr>           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">            <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">             Total accrued expenses            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,363,457            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>            <td style="padding-bottom: 2.5pt">            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">             $            </td>            <td style="border-bottom: Black 2.5pt double; text-align: right">             1,129,126            </td>            <td style="border-bottom: Black 2.5pt double; text-align: left">            </td>           </tr>          </tbody>         </table>        </div>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">         <b>         </b>        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">         <b>          NOTE H - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONAND NON-CASH INVESTING AND FINANCING ACTIVITIES         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         Cash payments for incometaxes were $1,025,000 and $1,100,000 for the years ended December 31, 2020 and 2019, respectively.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         As of December 31,2020, the Company had a number of unconverted Guardian shares that would convert to approximately 1,369 shares of United-Guardian,Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock.The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them tothe appropriate state jurisdictions. The Company is currently accruing dividends on the 1,369 shares that have not yet been exchangedor designated for escheatment as of December 31, 2020, and the Company will continue to do so as dividends are declared.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         During the third quarterof 2020, the Company paid approximately $124,041 to its transfer agent, which represented accrued dividends on unconverted Guardianshares. This payment was made to facilitate the conversion of those shares to United-Guardian, Inc. shares, and the subsequentescheatment of those shares to the appropriate state jurisdictions.        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 52; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">        <table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="text-align: center; width: 100%">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">             UNITED-GUARDIAN, INC.            </p>           </td>          </tr>         </tbody>        </table>        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE I - RELATED PARTY TRANSACTIONS         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         During each of theyears ended December 31, 2020 and 2019, the Company paid Bonamassa, Maietta, and Cartelli, LLP, $16,250 and $17,500, respectively,for accounting and tax services. Lawrence Maietta, a partner in Bonamassa, Maietta, and Cartelli, LLP (newly part of PKF O’Connor Davies), is a director of the Company.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <div data-td-statement-type="note">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">         <b>          NOTE J – SUBSEQUENT EVENTS         </b>        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">         On March 27, 2020,the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act containsa provision known as the Employee Retention Credit (“ERC”), a refundable payroll tax credit for qualified wages paidto retained full-time employees between March 13, 2020 and December 31, 2020. The Consolidations Appropriations Act (CAA), signedinto law on December 27, 2020, significantly modified and expanded the provisions of the ERC to include wages paid in the firsthalf of 2021. The Company has determined that it has qualified for this credit in the first quarter of 2021 and anticipates utilizingbenefits under this act to aid its liquidity position. For 2021, the ERC provides employers a refundable federal tax credit equalto 70% of the first $10,000 of qualified wages and benefits paid to retained employees between January 1, 2021 and June 30, 2021.Credits may be claimed immediately by reducing payroll taxes sent to the Internal Revenue Service. To the extent that the creditexceeds employment withholdings, the employer may request a refund of prior taxes paid.        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        F-22       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Rule-Page -->       <div style="margin: 3pt auto; width: 100%">        <div style="font-size: 1pt; border-top: Black 4pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>